LC-API/MS in Drug Metabolism and Pharmacokinetic Studies by Imrie, G A
Imrie,   Gregg   Andrew   (2007)   LC-API/MS   in   Drug   Metabolism   and 
Pharmacokinetic Studies. Doctoral thesis, University of Sunderland.
Downloaded from: http://sure.sunderland.ac.uk/3757/
Usage guidelines
Please refer to the usage guidelines at http://sure.sunderland.ac.uk/policies.html or alternatively 
contact sure@sunderland.ac.uk. 
LC-API/MS IN DRUG METABOLISM AND PHARMACOKINETIC STUDIES 
 
 
 
GREGG ANDREW IMRIE 
 
 
 
A thesis submitted in partial fulfilment of the 
requirements of the University of Sunderland 
for the degree of Doctor of Philosophy 
 
This research programme was carried out 
in collaboration with York Bioanalytical Solutions Limited 
 
 
July 2007 i 
________________________________________________________________________ 
 
Abstract 
 
The use of API interfaces with quadrupole mass spectrometers has been shown to give 
rise to good sensitivity, selectivity, and robustness for the interfacing of LC to MS.  Since 
their introduction in the 1990s the technique has rapidly become widespread, but at the 
outset of this research programme, there were still a number of problems associated with 
it, particularly when dealing with complex sample matrices.  The aim of this research 
programme was to study illustrative examples of the kinds of problems associated with 
the analysis of biological samples using LC-API-MS in an attempt to arrive at strategies 
which could be employed to eliminate, or at least compensate for, the problems. 
 
Commonly reported problems include the occurrence of matrix effects - a change in 
response of the target analyte(s) as a result of the presence in the samples of 
co-/late eluting interferences.  An  investigation  which  compared  ESI with APCI 
ionisation illustrated a significant drawback in the accepted methodology for the 
elimination of matrix effects. 
 
Optimal LC conditions for a number of assays may use non-MS-friendly mobile phases.  
A simple and convenient solution to this problem was found to  be the post-column 
addition of organic modifier, which reproducibly and reliably enhanced sensitivity. This 
approach was initially used for a range of dihydropyridine calcium channel blockers and 
was subsequently  applied to a range of chiral compounds from different therapeutic ii 
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groups to illustrate that this was  applicable as a generic technique for increasing 
sensitivity (typically by around an order of magnitude) in low organic mobile phases. 
 
Strategies to develop and validate methods for the determination of endogenous analytes 
in a biological fluid were investigated.  This involved the use of a surrogate matrix, to 
develop a method for the determination of endogenous testosterone in human serum and 
the use of non-matrix calibration standards for the successful development and validation 
of a method for the analysis of indolyl-3-acryloylglycine (IAG) in human urine.  
 
As a result of observations suggesting promotion of ionisation of deltamethrin in liver 
tissue sample extracts, it was postulated that this was due to the presence of high 
concentrations of surfactants.  After confirming the effect, a series of systematic 
investigations were performed to attempt to understand the mechanism to be able to 
utilise this as a general method for the enhancement of  signal with low sensitivity 
analytes.  It was found that the type of surfactant and concentration used was directly 
associated with an increased (or decreased) response.  
 
Although there remain a number of problems associated with the use of LC-API-MS, the 
work undertaken for this thesis has successfully demonstrated a number of techniques 
that can be applied to overcome these problems.  Knowledge of the nature of the sample 
undergoing analysis, the  required  analytical conditions,  and where required careful 
application of one of the techniques described will ensure that a robust method can be 
readily developed. iii 
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Chapter 1 
 
 
Introduction 
 
 
 
 
1.1  Analysis of Drugs in Biological Fluids and Tissues 
 
There are a number of reasons why it is necessary to analyse drugs in biological fluids, 
including in forensic toxicology, when looking for the presence of potential poisons, etc. 
[1] and in the monitoring of drugs of abuse [2].  However, the most common reason for 
this kind of analysis is to assist various stages of the drug development process [3].  
These include pharmacology, toxicology, metabolism and clinical trial testing. 
 
The programme of work described in this thesis was principally  concerned  with the 
analysis of pharmaceutical preparations where the concentrations in fluids are required 
for developmental purposes.  However, while the issues discussed principally involved 
illustrative examples of the determination of plasma and urine concentrations of known 
drugs, the range of examples covered extended to the analysis of an insecticide in animal 
tissues where similar problems may also be encountered. 2 
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The drug development process is both complex and time-consuming with many different 
disciplines involved in creating the overall strategy towards developing a successful drug 
candidate.  The process involves selection of a drug target and some (in vitro) efficacy 
testing, before selection of leading candidates based on a range of disciplines including 
toxicology,  pharmacokinetics  and pharmacodynamics.  These are followed by more 
wide-ranging and rigorous toxicological evaluations  and then extensive clinical trials 
before any submission of a drug candidate is permitted by the relevant regulatory 
authority.  A brief summary of the drug discovery and development process is illustrated 
in Figure 1.1, with the elements most relevant to this thesis falling under the “Pharma” 
heading. 3 
 
 
 
 
Figure 1.1  Schematic representation of the drug discovery and development process 4 
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As intimated already, drug bioanalysis is important in pharmacology studies.  At an early 
stage of the drug development process pharmacological studies are performed in order to 
determine the plasma (or other relevant fluid or tissue) concentration that will produce the 
required pharmacological response.  In many cases, at least as a simplified model for 
general use, the concentration of drug absorbed is directly proportional to the effect.  
Thus, at an early stage of development many drug analogues may be tested to determine 
their absorption.  This will usually take the form of a single dose given to several animals 
with the plasma concentrations being mapped over a suitable time period.  The analysis 
of these concentrations can provide information about the total absorption of the drug, 
which will generally be compared with other compounds that have similar chemical 
structures [4].  Thus the expected “active” part of the drug may be the same in all tests, 
with different side-groups attached to determine their effect in promoting or retarding 
absorption.  Although low absorption may not initially appear to be a problem (as the 
dose could be increased for a poorly absorbed drug), in practice it is considered desirable 
to have as high a degree of absorption as possible, in order to provide a predictable 
behaviour model.  For example, a drug with absorption of an average of 85% may, for 
example, vary from 80-90% between individuals, which represents a 12.5% variation in 
plasma concentration when comparing the lowest level to the highest.  However a drug 
with absorption of an average of 8% may vary from 5-10% absorption, which represents 
a 100% variation in plasma concentration when comparing the lowest level to the highest.  
Thus, the more predictable behaviour of the highly absorbed drug is generally preferred 
to the poorly absorbed drug. 
 5 
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Once the pharmacological profile of the drug has been established (together with various 
in vitro safety tests) toxicology testing begins.  This is essentially safety testing of the 
drug before it is allowed to be administered to man.  In toxicology testing, the aim is to 
determine the level at which adverse effects occur, or to confirm that no adverse effects 
occur up to a certain concentration [5].  The main aim of the bioanalytical investigations 
performed as part of toxicology testing is to confirm the presence and concentration of 
the dosed drug (or a suitable product or marker compound). 
 
Once a drug candidate is selected, based on a wide range of selection criteria from 
disciplines including molecular/cellular biology, chemistry, target specificity, cytological 
biomarker effects and drug metabolism [6], it then passes through the early stages of the 
toxicology testing process and moves on to clinical trials (i.e. testing in man).  This 
initially involves Phase I Clinical trials [7].  These are safety tests only, i.e. using healthy 
volunteers to determine that the drug candidate does not cause any adverse effects at 
various concentrations, eventually rising to the intended therapeutic dose levels. 
 
Metabolism studies to determine details of the absorption, distribution, metabolism and 
elimination of the drug are also carried out.  These help to determine the metabolic 
pathways of the drug as well as providing information about the storage/accumulation or 
elimination of the drug, which help in the design of a therapeutic dosing regime.  These 
are principally to help to justify the animal model chosen for the early toxicology work, 
by confirming the adsorption and distribution of the active part of the drug to the required 
therapeutic site [8].  Confirmation that the drug is not metabolised before having the 6 
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opportunity for efficacy is also provided by these studies.  These studies will typically be 
performed around the same time as pharmacokinetic studies, where the absorption, 
distribution, transformation and elimination in man are investigated.  
 
Formulation development is a key part of the drug development cycle which tends to take 
place at the same time as much of the Phase I and Phase II testing.  Phase II clinical 
testing tends to involve confirmation of the kinetic profile of the drug in diseased 
subjects, (to confirm that the profiles seen in healthy volunteers are similar in patients). 
 
There are a number of other trials performed over a similar time to some of the testing 
described above, including Proof of Concept and various other safety evaluations.  
Finally there are large scale (i.e. large numbers of subjects) clinical trials (some Phase II, 
but mainly Phase III) to provide substantive evidence for both safety and efficacy of the 
new drug candidate. 
 
All of the above testing stages require the use of robust bioanalytical methods to analyse 
the samples from those tests. 
 
1.2  Problems Associated with Biological Fluids 
 
The biological fluids that are most commonly analysed for drug concentrations are 
plasma (or serum) and urine.  In addition blood, saliva and many other fluids may be used 
depending on the chemical nature of the drug being analysed and the expected site of 7 
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action.  All of these matrices are complex matrices, i.e. they contain not only the drug 
being analysed, but also many thousands of other compounds, which can impact on the 
analytical methodology employed [9]. 
 
The main problem associated with plasma or serum analysis is the presence of large 
quantities of protein  [10].  Although the proteins will tend to have very different 
properties from the drugs being measured, there are frequently interactions between the 
proteins and drugs, which may impact on the analytical methodology.  In addition there 
are large quantities of lipids in plasma, which can also impact on the analysis. 
 
The main problems associated with urine are the presence of high concentrations of salts 
and the variation in concentration and content of urine which changes quite dramatically 
depending on diet, time of day, and various other factors.  Urine has a wide range of pH 
values  [11]  which may affect the drug, for example  by breaking it down into a 
degradation product [12]. 
 
1.3  Background 
 
In order to appreciate the aims and objectives at the outset of the research programme 
described in this thesis, it is necessary not only to consider drug bioanalysis but also to 
address the fundamentals of triple quadrupole mass spectrometry:  MS/MS created by 
connecting three quadrupole mass spectrometers in sequence.  The first “instrument” is 
used for precursor ion selection, the second as a collision tube for CID (collisionally 8 
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induced dissociation), and the third for detection of fragment ions created by dissociation 
of precursor ions [13]. 
 
 
Figure 1.2  Schematic representation of a triple quadrupole mass spectrometer.  Ions 
are generated at the ion source and drawn into the vacuum region of the mass 
spectrometer by a potential gradient.  Initial separation of the parent ion occurs in the first 
set of quadrupoles (Q1), then this passes into a second set of quadrupoles which act as a 
fragmentation, or collision cell (Q2) to produce fragment ions which are separated in the 
third set of quadrupoles (Q3).  These fragments then pass to an electron multiplier (EM) 
for signal enhancement prior to detection. 
 
 It is also necessary to be aware of the various existing approaches to overcoming typical 
analytical problems encountered in the use of high performance liquid chromatography 
(HPLC) with triple quadrupolar mass spectrometry for the analysis of analytes in 
biological samples and the challenges associated with these complex samples. 
EM 
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1.4  Hyphenated Techniques 
 
The need to develop increasingly sensitive and specific analyses for organic compounds 
has grown significantly in recent years. Initially this was due to the advent of the “new” 
atmospheric pressure ionisation (API) techniques developed in the early 1990s  [14] 
which enabled the analysis of compounds previously restricted to less specific, less 
sensitive or more complex techniques.  Following the establishment of API LC-MS over 
the 1990s this requirement had increased due to a combination of the need to identify and 
isolate metabolites and the adoption of the technique for Drug Discovery work, where 
only low sample quantities are frequently available [5, 15, 16]. 
 
The techniques used for such analyses have generally been hyphenated techniques as the 
complex sample matrices require substantial separation of matrix components from the 
analyte to enable the development of robust and specific analytical methods [17, 18, 19].  
For example, gas chromatography coupled with mass spectrometry (GC-MS) has been an 
excellent technique for the separation and quantitation of trace components in complex 
sample mixtures [20, 21], as well as in the confirmation of identity of unknown analytes 
[22]. 
 
A significant problem with GC-MS is that the analytes of interest must be volatile to be 
vapourised to allow separation in and elution from the gas chromatography column in the 
gas phase, prior to detection in the mass spectrometer.  Accordingly the compounds of 10 
________________________________________________________________________ 
 
interest must have a high degree of thermal stability to prevent degradation during 
separation and detection.  Unfortunately, these requirements preclude the use of GC-MS 
for most polar and high molecular weight molecules.  Critically, the majority of drugs in 
development over the last decade have fallen into one or both of these categories [23], 
with an increasing number of high molecular weight molecules being investigated due to 
advances in protein chemistry either as potential drug candidates  [24,  25,  26]  or, 
increasingly, as biomarkers that are used to determine the efficacy of drug 
candidates [27]. 
 
However,  high performance liquid chromatography (HPLC) is usually performed at 
around ambient temperatures and is an effective technique for the separation of such 
polar molecules.  Earlier detection techniques used in hyphenation with HPLC were 
based on absorbance of ultraviolet or visible radiation.  This is a simple, reliable 
technique, but has the disadvantage of low sensitivity when the analytes have no 
significant chromophore (i.e. a group of atoms that absorbs light) present.  In addition, 
there is low selectivity using this technique, in that analyte separation is based on 
retention characteristics which can be common among many completely different 
analytes.  In the context of samples that come from complex matrices (such as plasma 
and urine) it is not possible to separate the desired analytes from all background 
interferences [17, 18, 28]; therefore additional resolving power needs to be added to the 
analytical technique being employed. 
 11 
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Fluorescence and electrochemical detectors can extend the sensitivity range of UV-vis 
detectors by two or three orders of magnitude [29, 30], if the compound exhibits (or can 
be made to exhibit) fluorescence or electroactivity.  Such techniques also improve 
specificity, but are limited in range of application in that many compounds can not easily 
be made to exhibit these properties, without complex and potentially non-robust sample 
preparation methodologies. 
 
Mass spectrometers provide both high sensitivity and selectivity.  However, the problem 
with hyphenation of LC  (a technique for the separation of complex mixtures that relies 
on the differential affinities of substances for a liquid mobile medium and for a stationary 
adsorbing medium through which they pass) and MS (an analytical technique used for 
separating ions or molecules that are dissolved in a solvent) was that mass spectrometers 
operate under high vacuum (<10
-5 Torr) and there is a requirement for the removal of the 
large volumes of mobile phase used in HPLC (liquid chromatography using tightly 
packed columns containing microspheres, where the mobile phase is pumped through the 
column with a high pressure pump) before MS analysis.  In addition, in liquid 
chromatography the analytical species are generally not  ionised in the liquid phase; 
whereas for mass spectrometric detection the analytes are required to be ionised in the 
gas phase.  This results in a fundamental incompatibility between the two techniques. 12 
________________________________________________________________________ 
 
Previous approaches for the combination of LC and MS have included use of the moving 
belt  interface  [31], direct liquid introduction  (DLI)  [32], particle-beam  [33]  and 
thermospray [32].  The main disadvantage with these techniques was that they required 
the removal of large amounts of solvent vapour from the vacuum system of the mass 
spectrometer.  For example with the moving belt interface as illustrated in Figure 1.3 if 
evaporation is incomplete liquid passing into the mass spectrometer can cause significant 
pressure fluctuations leading to poor performance and reduced sensitivity. 
 
 
Figure 1.3  Schematic representation of moving belt interface [34].   
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1.5  Development of LC-MS Interfaces 
 
The practical problems associated with the development of an LC-MS interface are much 
more severe than those associated with GC-MS interfacing.  There are three particular 
difficulties: 
 
a)  high flow rates 
b)  involatile and labile samples 
c)  use of involatile buffers 
 
The effective flow rates (i.e. in terms of vapour into the system) are much higher in LC 
than in GC and considerable energy input is required to separate the flow of solvent from 
the solute as vapour.  A conventional source housing pumping system gives a pressure of 
2.5 x 10
-4  Torr when the flow rate of vapour into the system is of the order of 
5-7 mL.min
-1. 
 
With the exception of the specially designed Thermospray ion source (where the majority 
of the liquid flow is volatilised as it emerges from a heated capillary, Figure 1.4), all of 
the flow that enters the ion source to be ionised is then directed into the source housing to 
be pumped away. 
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Figure 1.4  Schematic representation of thermospray ionisation process [35].  The 
analyte is ionised following ion-molecule reactions with reagent gas ions.  The reagent 
gas ions are electrolytic ions generated when the sample solution is sprayed by heating 
from the end of a capillary tube under a low vacuum. 
 
There were a number of possible solutions to the problem of restricted solvent flow rate 
that were available to the pioneers in the field of LC-MS as detailed below.  
 
a)  Splitting the flow from a conventional LC column and introducing only a fraction 
of this flow into the mass spectrometer.  This course of action wastes a high 
proportion of the sample and is not acceptable if the sample quantity is limited 
[36]. 
b)  Increasing the source housing pumping speed, for example (in the Sciex API III) 
by the addition of a cryopump.  Under these circumstances, the maximum 
permissible flow rate may be increased. 15 
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c)  Using low flow narrow-bore packed capillary (with a typical internal diameter of 
1 mm
 [37]) or open tubular columns that eliminate the need for flow splitting [38]. 
d)  Removal of the solvent prior to introduction of the sample into the mass 
spectrometer.  This approach was used in the transport and particle beam 
interfaces,  although the technique requires the sample to be at least partially 
volatile, and has limited tolerance to the kinds of buffers used in routine liquid 
chromatography [39]. 
e)  Attaching additional pumping to the ion source itself, which can then accept much 
higher flow rates.  This approach was used in the thermospray interfaces 
(Figure 1.4, [40]). 
f)  Ionisation at atmospheric pressure (Atmospheric Pressure Ionisation, API).  This 
has the advantage that a curtain gas can be introduced to strip away solvent 
molecules prior to entry of the analyte(s) into the high vacuum mass spectrometer.  
Accordingly thermally labile compounds are more amenable to analysis using 
API techniques. 
 
In many cases, the materials being analysed by LC-MS are relatively involatile and/or 
labile since they are generally compounds that are not amenable to GC-MS analysis.  
Conventional ionisation techniques such as electron impact* and chemical ionisation
# are 
gas-phase ionisation techniques, which require thermal volatilisation of the sample.  
Although this limitation is acceptable for some compounds that can be analysed by LC, it 
is unsuitable for a larger number.  For this reason, considerable use has been made of 16 
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liquid-phase ionisation techniques such as thermospray ionisation, continuous-flow fast 
atom bombardment
** and electrospray ionisation [41]. 
 
*Electron Impact Ionization (EI):  The sample is vaporised into the mass spectrometer ion 
source, where it is impacted by a beam of electrons with sufficient energy to ionise the 
molecule.  This is a low energy process where the principal ions produced are protonated 
[M+H]
+ or deprotonated [M-H]
- [42]. 
 
#Chemical ionization (CI) is a technique where the analyte is ionized by chemical 
ion-molecule reactions during collisions in the ion source.  The reagent gas is ionised and 
this then ionises the analyte by charge transfer.  As with EI, this is a low energy process 
where the principal ions produced are [M+H]
+ or [M-H]
- [43]. 
 
**Fast atom bombardment (FAB) is a form of ionization where a fast moving beam of 
neutral atoms (typically Argon or Xenon at 8 keV) bombard a metal target coated with a 
liquid matrix (typically glycerol or 3-NBA) in which the sample has been dissolved.  This 
is a soft ionization technique, i.e. does not result in significant fragmentation and 
produces mainly protonated or deprotonated molecules  [44].  Continuous-flow FAB 
(CFAB) is a form of FAB in which the dissolved sample is introduced continuously to the 
sample probe [45]. 
 
Most LC-MS interfaces and/or ion sources do not accept the use of involatile buffer 
systems, as there is no simple way to prevent these from the entering the high vacuum 17 
________________________________________________________________________ 
 
regions of the mass spectrometer, leading to contamination and loss of vacuum (and 
therefore sensitivity).  Unless a transport interface is being used, volatile buffers based on 
materials such as ammonium acetate, ammonium formate, ammonium hydroxide, and 
acetic or trifluoroacetic acid should be used [46]. 
 
To sum up the situation, a number of different approaches have been used in interfacing 
LC and MS.  The earliest attempts focused on methods of overcoming the incompatibility 
of the liquid flow rate and maintenance of the mass spectrometer high vacuum, while 
more recently (in particular since the development of the electrospray interface by Fenn 
and Yamashita in 1984 [47]), more attention has been focused on the practical use of 
ionisation techniques that do not require sample volatilisation. 
 
1.6  Atmospheric Pressure Ionisation 
 
The principal requirement for mass spectrometric analysis is to have the ability to ionise 
the analyte being investigated [48].  The degree to which the desired analyte ions are 
formed and the ability to discriminate the analyte ions from other, potentially interfering, 
species are the keys to providing the sensitivity and selectivity required to produce an 
acceptable analytical method using this technique.  The design of the ion source is critical 
to the formation of the analyte ions and is therefore the key starting point for any mass 
spectrometric technique. 
 18 
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Development of atmospheric pressure ionisation (API) has resulted in a major 
improvement in the interfacing of LC and MS.  In particular, ion-spray 
(pneumatically-assisted electrospray) [49] and atmospheric pressure chemical ionisation 
[50] (APCI) interfaces have been shown to be sensitive, selective, and most importantly, 
robust techniques for the interfacing of LC to MS.  More recent developments include 
atmospheric pressure photoionisation (APPI) [51], which utilises a vacuum-ultraviolet 
lamp as a source of photons, and sonic spray ionisation (SSI) [52], which utilises a very 
high gas flow (“sonic”, i.e. at the speed of sound) to deliver the analyte to the mass 
spectrometer.  Both of these techniques have the advantage over APCI and ion-spray that 
high voltages or high temperatures are not required, which allows the analysis of 
thermally labile compounds. 
 
Part of the success of API is due to the compatibility of the API interfaces with 
conventional LC conditions.  For example, APCI  can use the whole LC flow from 
conventional 4.6 mm i.d. columns (i.e. 1.0 mL.min
-1) for analysis.  Meanwhile, ion-spray 
and the heated version of ion-spray, e.g. TurboIonSpray (PE Sciex), are compatible 
with the flows from microbore LC columns. 
 
In API LC-MS, ions are formed from a liquid flow introduced into a source region 
maintained at atmospheric pressure; therefore  the  ion source contains sample ions 
together with solvent vapour and the ambient gas (usually nitrogen).  The coupling of a 
liquid flow inlet to an API source offers some advantages over other approaches.  For 
example, it avoids problems associated with the introduction of a liquid flow directly into 19 
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high vacuum.  Again, it readily allows liquid chromatography systems, especially low 
flow systems such as capillary electrophoresis columns, to be operated under “normal” 
conditions, i.e. with the column exit at atmospheric pressure. 
 
There are four forms of ionisation used in API sources for LC-MS: 
a)  Atmospheric pressure plasma ionisation 
b)  Electrospray 
c)  Ion spray 
d)  Sonic spray 
 
Atmospheric pressure plasma ionisation consists primarily of atmospheric pressure 
chemical ionisation (APCI) and the relatively recent atmospheric pressure photo 
ionisation (APPI), introduced by Robb, Covey and Bruins in 2000 [53]. 
 
The APCI interface (Figure 1.5) uses pneumatic nebulisation to convert the liquid flow 
into droplets which are then swept by means of a sheath gas through a quartz tube heater 
to vapourise the solvent and analyte.  The mixture of vapourised solvent and analyte 
flows towards the ion formation region where a corona discharge initiates chemical 
ionisation at atmospheric pressure (APCI) using the vapourised solvent as the reagent 
gas.  These CI processes take place within a wall-less reaction region, which is defined by 
the gas flow in the source volume.  Flow rates from 0.5 to 2 mL.min
-1 of solvent and the 
use of volatile or involatile buffers are permitted.  Memory effects are minimised by the 
large-scale, open construction of the source volume. 20 
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Figure 1.5  Schematic representation of Sciex APCI interface. 
 
One method used in transferring ions from an  APCI source into a mass analyser  is 
illustrated in Fig. 1.5.  Ions are driven towards a sampling orifice (approximately 125µm 
in diameter), that leads directly from atmospheric into the mass spectrometer vacuum 
system, by a combination of gas flow and electric fields.  The flow of an inert barrier gas 
(nitrogen in the illustration) across the sampling orifice can be used to minimise the 
number of neutral solvent molecules that enter the vacuum system.  The same barrier gas 
will also quench any ion-molecule reactions initiated by the corona discharge.  With this 
sampling method, a very high pumping speed, provided in earlier generations of 
instruments by cryopumping and cryotrapping, and more recently using ultra-high speed 
Turbo pumps, is used to maintain a suitable operating pressure. 
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An alternative interfacing method for API sources uses a larger sampling orifice 
(approximately 200-300 µm in diameter), which leads into an intermediate vacuum stage.  
Successive vacuum stages may be used to improve the ion-to-neutral ratio in the stream 
which eventually enters the mass analyser by preferentially pumping away neutral 
molecules while ions are directed towards the next orifice by means of electric fields.  As 
in all LC-MS interfaces, the neutral flow has to be reduced to a level at which the mass 
spectrometer pumping system can maintain a good working pressure. 
 
In both electrospray and ionspray an electric field is generated at the tip of the sprayer by 
the application of a high voltage range directly on to the sprayer, with a counter electrode 
a few millimetres away.   
 
IonSpray is pneumatically assisted electrospray, where the liquid carrying the analytical 
sample (i.e. the LC column effluent) is passed through a sprayer which is maintained at 
high voltage, in order to ensure that a mist of highly charged droplets is formed.  As the 
droplets evaporate, ions are ejected into the gas phase by a low energy process that does 
not induce fragmentation [54]. 
 
A comparison of the three main atmospheric pressure techniques reveals differences in 
the type of compounds that can be analysed and the  liquid flow rates that can be 
accommodated. The electrospray and ion-spray techniques are based on the desorption of 
ions from small droplets with virtually no heat input and are therefore very suitable for 
highly polar molecules.  The heated nebuliser, on the other hand, depends on a gas-phase 22 
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ionisation process and is therefore only suitable for moderately involatile or labile 
molecules.  The APPI interface is suitable for extremely non-polar compounds, and is 
ideal for the analysis of biological molecules such as steroids [55, 56]. 
 
Atmospheric pressure photoionisation utilises a very high gas flow (“sonic”, i.e. at the 
speed of sound) to deliver the analyte to the mass spectrometer.  The PhotoSpray
TM 
source utilises a vacuum-ultraviolet lamp as a source of 10 eV photons.  A specially 
selected mobile phase additive, the dopant  (e.g toluene  [57]), is used to enhance 
photoionisation, by creating large numbers of ionised dopant molecules.  This excess of 
charged dopant molecules created a cascade of ion-molecule reactions involving 
protonated solvent clusters as intermediate species leading to the final protonation of the 
analytes.  This is the principal form of ionisation in the PhotoSpray
TM source and is 
typically more intense than in APCI for non-polar compounds.  In addition, there is a 
secondary mode of ionisation within this source, which involves charge transfer directly 
from the ionised additive to the analyte. 
 23 
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Figure 1.6  Schematic  representation of atmospheric  pressure  photoionization.  
PhotoMate source, Agilent Technologies, www.agilent.com 
 
An alternative interfacing method for API sources used a larger sampling orifice 
(approximately 200-300 µm in diameter [58]) which leads into an intermediate vacuum 
stage.  Successive vacuum stages are then used to preferentially pump away neutral 
solvent molecules while analyte ions are directed towards the next orifice by means of 
electric fields.  As in all LC-MS interfaces, the neutral flow has to be reduced to a level at 
which the mass spectrometer pumping system can maintain a good working pressure. 
 24 
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Figure 1.7  Schematic representation of electrospray ionization.   
 
IonSpray is pneumatically assisted electrospray, where the liquid carrying the analytical 
sample (i.e. the LC column effluent) is passed through a sprayer which is maintained at 
high voltage, in order to ensure that a mist of highly charged droplets is formed.  As the 
droplets evaporate, ions are ejected into the gas phase by a low energy process that does 
not induce fragmentation [59].  The liquid effluent is either infused at low flow rates, or 
more typically, split so that approximately 20 µL.min
-1 reaches the interface.  Preformed 
ions in solution are desorbed from highly charged droplets by a process known as ion 
evaporation.  The ion-spray interface is operated at ambient temperature, which results in 
a mild ionisation process, leading to molecular ion formation.  Once formed, the ions are 
again passed through a curtain gas into the vacuum region of the mass spectrometer. 
 25 
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A commonly used modification of ion-spray is the TurboIonSpray
TM, which uses a heated 
drying gas to aid ion evaporation, thereby allowing higher solvent flows (up to 
1 mL.min
-1) to the mass spectrometer. 
 
Sonic spray ionisation generates molecular ions using a neutral mobile phase.  Charge 
separation occurs around the surface of the solution, then vaporisation is enabled by 
passing a fast gas flow over the surface to produce electrically charged droplets.  
Although developed in 1994 [60], this technique has not seen widespread use to date. 
 
Differences in the nature of the main atmospheric pressure techniques make them more or 
less suitable for both the ideal types of compounds that can be analysed by a particular 
technique and the liquid flow rates that can be accommodated by the technique.  As 
electrospray and ion-spray are based on the desorption of ions from small droplets with 
minimal heat input, they are therefore ideal for highly polar molecules.  The heated 
nebuliser, however, utilises a gas-phase ionisation process and is therefore only suitable 
for moderately involatile or labile molecules.  The APPI interface is suitable for 
extremely non-polar compounds, and is ideal for the analysis of biological molecules 
such as steroids [55, 61].    
 
Part of the success of API is due to the compatibility of the API interfaces with 
conventional LC conditions.  For example, APCI can use the whole LC flow from 
conventional 4.6 mm i.d. columns (i.e. 1.0 mL.min
-1) for analysis.  Meanwhile ion-spray 
and the heated version of ion-spray, e.g. TurboIonSpray
TM (PE Sciex) are compatible 26 
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with the flows from microbore LC columns.  In API LC-MS, ions are formed from a 
liquid flow introduced into a source region maintained at atmospheric  pressure.  
Therefore the ion source contains sample ions together with solvent vapour and the 
ambient gas (usually nitrogen).  The coupling of a liquid flow inlet to an API source 
offers some advantages over other approaches.  For example, it avoids problems 
associated with the introduction of a liquid flow directly into high vacuum.  Again, it 
readily allows liquid chromatography systems, especially low flow systems, such as the 
output from a capillary electrophoresis interface, to be operated under “normal” 
conditions, i.e. with the sample exit from the initial separation technique at atmospheric 
pressure. 
 
Current developments include a combined electrospray and APCI interface [62], which 
allows alternate electrospray and APCI scans with switching polarity possible within a 
single sample run.  The ability to use both types of ionisation combined with both 
polarities of ionisation is expected to enable a sharp reduction in instrumentation time 
required for development of future methods, or when utilised for the analysis of complex 
compound mixtures.  The requirement to optimise tuning parameters in either mode still 
exists, and whether there is a reduction in sensitivity in each mode remains to be 
established. 
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1.7  Quadrupole Mass Analyser 
 
The principal type of mass spectrometers used for the quantification of drugs in 
biological fluids is the triple quadrupole mass spectrometer [63].  
 
Ions from the source (interface) enter the mass analyser region under an accelerating 
potential of around 5-15 V.  Pairs of rods have a two component voltage applied to them 
–  one set have a standard DC potential, with the other set having an alternating 
radiofrequency (RF) component. 
 
Ions follow an oscillating trajectory between the rods, with only ions of a specific kinetic 
energy passing between the rods and out the other end.  All other ions collide with the 
rods. The selected ions enter a collision cell, where collisions with an inert gas lead to 
fragmentation.  These collision cells are typically a second quadrupole, with only 
alternating RF present, to focus the ions.  The ions enter the collision cell with a low 
energy (in the region of 100 eV).  This low ion velocity and the relatively long ion path of 
a quadrupole collision cell increase the possibility of multiple collisions.  The fragments 
(product ions) are then passed through a second set of mass selection quadrupoles so that 
only fragments of a particular kinetic energy emerge from the mass analyser to the 
detector. 
 
The signal is usually then amplified prior to entering the detector region, e.g. using an 
electron multiplier, before being sent for detection and interpretation. 28 
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The specificity obtained by the use of the triple quadrupole mass spectrometer is 
particularly important when the original sample is  in a complex matrix, containing 
numerous, chemically similar, compounds which would lead to high background noise, 
without the specificity generated by MRM.  All samples from biological matrices fall into 
this category, whether urine, blood, plasma, or some other biological fluid or tissue.  As 
these are the kinds of samples required for analysis in the development of pharmaceutical 
products, this covers a wide range of sample analysis types of relevance to the research 
programme described in this thesis. 
 
Although these techniques can allow the analysis of a number of compounds that were 
previously unsuitable for mass spectrometric methods, there are large differences in the 
suitability of each technique to various compound classes. 
 
1.8 Aims and Objectives 
 
Although liquid chromatography with triple quadrupole mass spectrometry has become 
the pre-eminent technique used for the analysis of drugs in biological fluids, there remain 
a number of problems to be resolved, or reduced.  The aim of the research programme 
was to investigate a number of the more common problems and determine ways to 
eliminate the problems, or reduce them to an acceptable level.  The focus of the 
investigations was on the ionisation process itself. 
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Initially, the project focused on developing a range of novel approaches to some of the 
most scientifically challenging of the  bioanalytical applications to more effectively 
exploit the significant advantages of LC-API/MS.  The effects of co-eluting and late 
eluting compounds in samples produced from pharmacokinetic studies was investigated, 
to determine efficient and robust methodologies for reducing or eliminating the matrix 
effects that these compounds were responsible for.  As part of this investigation, the 
mode of ionisation used was investigated, to determine whether some matrix effects may 
be alleviated using a simple change in ionisation mode.   
 
Other studies included  an investigation into the application of the technique of 
post-column modification of mobile phase, where the optimum chromatographic 
separation required a non-MS-friendly mobile phase to be used.  The aim was to enable 
the development of a robust method, without changes to the initial chromatographic 
separation, thereby enabling an established separation methodology to be used whilst 
making the analytical instrumentation capable of operating at the required limits of 
detection. 
 
The problem of developing robust and specific methods for the analysis of endogenous 
analytes is often encountered in the analysis of biological samples.  Investigations were 
made using working examples to illustrate the suitability of several methods to overcome 
the problems created by this issue, including utilising a surrogate matrix and getting truly 
representative blank matrix to develop an assay. 
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Finally, as a result of observations made during previous work and with the knowledge 
gained of the mechanism of ionisation and associated factors which combine to provide a 
suitable method for analysis, an investigation into the addition of surfactants to samples 
in order to affect the response of target analytes was made, with the aim of increasing 
sensitivity for a specific analyte. 
 
In each of the separate application studies, in order to properly investigate the issues 
discussed there was a thorough investigation into factors that affected the sensitivity, 
specificity, accuracy and precision of LC-API/MS in bioanalysis.  This included  an 
examination of the influence of factors such as matrix effects, sample preparation 
modalities, ionisation technique and mobile phase design.  These issues of optimisation 
of experimental variables were embodied in the individual application studies. 
 
The focus has always been on relatively easy to apply modifications of standard 
techniques in order to increase the applicability of these modified techniques for a wider 
range of analyte types. 
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Chapter 2 
 
 
Modification of Analyte Response Due to Matrix Effects 
 
 
 
 
As intimated previously, one of the most common problems encountered in the analysis 
of samples in biological matrices is as a result of so called “matrix effects”, i.e.  
modification of analyte response as a result of the presence of chemical components of 
the sample matrix. 
 
There are two main causes of matrix effects in bioanalytical analysis using HPLC as the 
principal separation technique – those caused by co-eluting compounds and those caused 
by late-eluting compounds: 
 
Co-eluting compounds:
 
  These are compounds with similar retention characteristics to the 
analyte(s) of interest, under the chromatographic conditions employed, which therefore 
elute from the sample separation stage at approximately the same time as the target 
analyte(s). 32 
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Late-eluting compounds:
 
  These are compounds that are more strongly retained on the 
retention medium under the chromatographic  conditions employed (in HPLC -  the 
stationary phase on the analytical column) than the target analyte(s).  For example if the 
target analyte has a retention time of 3 min, with a total sample run time of 5 min, then a 
late-eluting compound that elutes after 8 min will co-elute with the target analyte after the 
first sample. 
Time (min) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Analyte A
1 A
2 A
3 A
4
Matrix effect compound M
1 M
2 M
3  
 
Figure  2.1  Comparison of elution time of target analyte (A) and potential 
late-eluting interferent (M).  Assumes a run time of 5 min, with no pause between 
samples.  The superscript number indicates the sample injection number, i.e. M
1 is the 
matrix effect compound elution time from injection 1, which co-elutes with the target 
analyte elution time from injection 2 (A
2). 
 
In this example (Figure 2.1) the co-elution occurs from the second sample onwards.  With 
the relative retention times selected for this example co-elution occurs for all samples 
after the first, but it could just as likely be from the 3
rd, 4
th, 5
th, etc.  In addition, the 
co-elution need not necessarily occur on all samples after a particular time point.   This is 
one of the main reasons that some methods can suffer from matrix effects in early 
development as it is not always apparent that there is a problem with only a few samples 33 
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injected.  A further problem with late-eluting interferents is potential cumulative effects 
(Figure 2.2). 
 
 
 
 
Figure 2.2  Cumulative effect of late-eluting compound.  The matrix effect-inducing 
compound illustrated has a long chromatographic tail, which in successive injections falls 
under the “main peak” of the compound.  This will lead to an increase in the matrix effect 
observed through the course of a chromatographic run.  In the example shown the 
cumulative effect is not highlighted. 
 
Essentially both types of interferences to an assay are similar in both cause and effect – 
the presence of interfering compounds causes a change in response of the target analytes 
in the mass spectrometer, which makes the development and validation of robust and 
accurate analytical methods difficult.  The majority of matrix effects result in suppression 
of the analyte signal, e.g. as discussed by Annesley [64], although much less usually in 
some cases the presence of these interfering species can cause enhancement of the analyte 
response  [65].  The critical problem associated with matrix effects is the lack of 34 
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robustness of the method, as the degree of suppression (or enhancement) would be 
expected to vary considerably from sample to sample. 
 
In addition the same effect can be the result of the “dosing vehicle effect” [66], the dosing 
vehicle being the agent that serves as a carrier used to disperse or solubilise the test item. 
 
This is  an increasingly common problem where the vehicle used for (particularly) 
intravenous dosing causes modification of ionisation of the target analytes [67].  The 
main problem with this is that it is an effect that is not typically considered during the 
early stages of the development and validation of a method, which typically occurs in 
isolation to the vehicle selection process.  This type of effect is most often only detected 
when using a stable isotopically-labelled internal standard within the analysis.  In full 
method development it is important to consider this as a possible effect and carry out a 
small amount of additional development prior to the analysis of valuable (both ethically 
and financially) samples. 
 
In addition, during the Discovery stage of drug development it is usual to perform only 
limited method development.  At this stage significant matrix effects caused by the 
dosing vehicle can even result in the rejection of perfectly viable drug candidates at an 
early stage as their bioavailablity may appear to be low due to poor “recovery” compared 
with other candidate drugs [68].  In Discovery investigations care should be taken to 
minimise any vehicle effects that may lead to rejection of viable drug candidates [69].   
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Strategies for the elimination, or at least control, of these effects are discussed in the 
following sections, for different types of problems encountered. 
 
As  illustrated in Figures 2.1 and 2.2  late-eluting interferences occur as a result of 
compounds which are retained on the HPLC stationary phase for a longer period than the 
target analyte(s). 
 
There are four main approaches to dealing with compounds associated with late-eluting 
interferences that may normally be adopted: 
 
a)  Greater sample clean-up to remove the interfering compounds from the samples [70].  
Overall, this is always preferable as the “cleaner” the sample the more robust the final 
method is likely to be.  There are a number of reasons to not adopt this strategy 
including limitations on the chemical nature of the target analyte (which preclude 
very specific sample preparation methodologies), time constraints on developing the 
method and the requirement to analyse multiple target analytes of differing chemical 
natures.  All of these may make greater sample clean-up impracticable without 
significant material loss, which may be a significant factor, particularly when the 
available sample volumes are limited. 
b)  Modification of the mass spectrometric conditions [71] (including, if necessary, the 
mode of ionisation being used) to reduce the effects that the late-eluting interferents 
have on the analytes of interest.  The mass spectrometric conditions will routinely be 
optimised for the target analyte(s), but sometimes the conditions that produce the 36 
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greatest response in solutions of the analyte(s) are less optimal when using extracted 
samples.  Mass spectrometric conditions are routinely optimised using a “pure 
standard solution” (i.e. a solution containing only a suitable solvent and the target 
analyte).  Re-optimising  the mass spectrometer  conditions with pooled extracted 
samples is an additional step that, although time-consuming, can potentially remove 
or reduce any problems associated with the sample matrix. 
c)  Modification of the chromatography to ensure that the interferents no longer elute at 
the same time as the analytes of interest [72].  The effectiveness of this strategy is 
dependent on the differences in chemical properties between the target analyte(s) and 
the potentially interfering species.  This can be a particularly difficult strategy to 
employ if the analysis is for multiple analytes, which require chromatographic 
separation (e.g. structural or optical isomers), as any attempt to remove the potential 
interferents will impact on the required chromatographic resolution. 
d)  Use of a post-sample gradient to ensure that the late-eluters are removed from the 
analytical column before the introduction of the next sample [73].  This is perhaps 
the simplest strategy to employ, as the only significant  negative factors are an 
increased run time and increased use of solvents, etc. 
 
In practice, the methodology employed to eliminate, or control matrix effects, is usually a 
compromise between the four available methods, to reduce the interferences as 
comprehensively as possible, whilst minimising method development time and 
maintaining relatively short sample analysis times (compared to traditional techniques 
such as HPLC). 37 
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The simplest method to try is modifying the mass spectrometric conditions; in particular, 
this might often involve changing the mode of ionisation to APCI. 
 
Previous work involved the validation of a  method for the analysis of a new drug 
candidate undergoing investigation in dog plasma in accordance with recognised 
international standards  [74].  This validation exercise involved confirmation that the 
assay being described was precise, accurate and robust over the range investigated. 
 
In the course of developing a method for the analysis of the same compound in dog urine, 
the intention was to use the same methodology, where possible, for analyst convenience 
and, it was assumed, in order to minimise the time required to develop a robust analytical 
method.  Accordingly, with the exception of the sample preparation method, all steps of 
the method applied were initially identical, i.e. the chromatographic  and mass 
spectrometric conditions were identical.  Initial results showed  poor precision and 
varying accuracy in all quality control samples.  Quality control samples consisted of six 
replicates at each of five concentrations across the planned linear concentration range for 
the assay.   
 
The presence of late-eluting interferents had not initially been detected using the now 
common method of post-column infusion of the compound whilst injecting matrix 
blanks.  This was because the isocratic mobile phase conditions, which were optimised 
for the new drug candidate, only resulted in allowing these late-eluting interferents to 38 
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enter the mass spectrometer, and therefore be detected, approximately one hour after 
injection. 
 
Included in  the earlier investigation (producing poor precision) were “matrix effect 
samples”, which consisted of six separate individual sources of matrix (i.e. urine taken 
from six different dogs) which was spiked to three separate concentrations at the low end, 
middle and high end of the planned concentration range.  Normally a matrix effect is 
illustrated by poor precision for these samples (as they consist of different matrices, 
therefore potentially different quantities of interfering species); however with late-eluting 
interferences which elute so long after the target analyte, these samples may not (and in 
this case did not) highlight the problem (i.e. they were as inconsistent as the other quality 
control sample sets).  Often, poor precision for quality control samples may be as a result 
of system effects such as partial blockage of the LC or mass spectrometric system.  
However in this case the internal standard (which was similar in structure to the target 
analyte) produced a consistent response throughout the run; therefore system effects 
could be discounted.  It was thus suspected that a matrix effect caused by late-eluting 
interferences was the cause. 
 
 In order to confirm that the differences in response of the matrices was a real effect and 
not as a result of inconsistent spiking or sample preparation, a solution of the target 
analyte was infused through a tee-piece at the same time as a blank injection of extracted 
matrix was injected onto the chromatographic system, with the sample run time increased 
to 2 hours.  The response of the analyte was seen to be acceptable (i.e. no significant 39 
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change in response) at the analyte retention time; however after approximately one hour 
under the conditions used, there was a significant drop in analyte response for a period of 
approximately 5 minutes.   This confirmed that the matrix effects observed were as a 
result of late-eluting interferences, which were only detected after a large number of 
samples were injected (run time for plasma method using the same isocratic conditions 
was 6 min). 
 
Of the main strategies for the elimination of such interferences previously described it 
was decided to try to eliminate the matrix effects by the simplest means possible, i.e. by 
changing the mode of ionisation from pneumatically assisted electrospray to atmospheric 
pressure chemical ionisation (APCI).  (The sample preparation involved relatively 
specific sample clean-up using mixed-mode solid phase extraction cartridges; therefore it 
would have been expected to take a long time to eliminate the interferences by modifying 
the sample preparation methodology).  Although in some cases APCI may be susceptible 
to significant matrix effects [75] it is generally considered to have reduced and in many 
cases no matrix effects [68].  The change from pneumatically assisted electrospray to 
APCI often reduces or eliminates matrix effects as the mode of ionisation is completely 
different; therefore the chemical properties that are responsible for causing the matrix 
effect may not be relevant.  In general, ion suppression in electrospray ionisation can be 
considered to be caused by the presence of non-volatile solutes in the mass spectrometer 
source spray, which alter the droplet solution properties, thereby altering the response 
that would be expected for the target analyte [76]. 
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This simple change, with no effects on the sample preparation methodology or 
chromatographic separation reduced the effects that had previously been observed to 
negligible proportions.  Although change of mode of ionisation was sufficient to 
eliminate this suppression of ionisation as a result of late-eluting interferents, an 
additional chromatographic step  was added, consisting of the introduction of a rapid 
gradient after the time of the elution of the analytes of interest.   Although at first glance 
this may appear a superfluous step, it was included to ensure that as many of the 
interferents as possible could be removed without significantly affecting analysis time.  If 
these interferents were not removed it was considered a possibility that, over the course 
of multiple analytical batches, a build-up of late-eluters could occur, which might result 
in matrix effects even after the change in mode of ionisation to APCI. 
 
As the isocratic conditions for the sample analysis utilised acetonitrile  -  ammonium 
acetate (40:60, v/v); introducing a rapid gradient to 100% acetonitrile over 1 min, then 
leaving at 100% acetonitrile for 1 min resulted in an increased run time of 4 min 
(including time to re-equilibrate to the original conditions).   This increase from a sample 
run time of 6 min to 10 min although undesirable from an efficiency standpoint was 
considered to be easily acceptable as an additional safeguard to the validation of a robust 
analytical method for the required analysis. 
 
The use of these two small modifications to the validated (in plasma) method allowed the 
new method (in urine) to be validated to the same rigorous internationally recognised 
standards. 41 
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This simple approach meant that only one or two additional days of development time 
was required to solve the problems encountered with the method, rather than several 
weeks, which would be more likely if the sample preparation methodology and overall 
chromatographic conditions had to be radically altered, by effectively restarting the 
development as a completely new method (rather than as a modification of an existing 
method). 
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2.1  An Approach to Dealing with Matrix-Related Suppression of Ionisation 
caused by Co-Eluting Interferences:  The Influence of Ionisation Mode on Ion 
Suppression in LC-MS/MS  –  A Comparison Between Electrospray and 
Atmospheric Pressure Chemical Ionisation 
 
2.1.1  Introduction 
 
 
Liquid chromatography-tandem mass spectrometry has become the current principal 
analytical technique for the quantitative analysis of drugs and drug metabolites in 
biological matrices  [16,  35].  Use of tandem mass spectrometry provides a highly 
selective methodology; therefore theoretically sample clean-up and chromatographic 
separation can be reduced compared to other less selective methodologies.  However 
there are still a number of potential problems with the techniques, with one of the most 
significant being ion suppression [64, 77].  As discussed earlier, the principal causes of 
ion suppression are the presence of coeluting, or less-commonly, late-eluting compounds 
in the prepared sample.  The presence of these compounds results in competition with the 
desired analyte ions for the surface of the droplet undergoing ionisation in electrospray 
[78], or direct competition for charge in APCI [75]. 
 
The presence of ion suppression can be evaluated in several ways, but is most commonly 
investigated by infusion of a solution of the test compound(s), which is added into the 
eluent stream post-column via a tee-piece [77].  Samples of blank matrix are injected 43 
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under normal chromatographic conditions and the effect on the response of the infused 
compound(s) monitored.  Theoretically the infused compound should produce a straight 
line of response over time, but typically in practice there is a significant drop in response 
which corresponds to the void volume of the analytical column and there may be other 
changes in response (usually reductions, though less typically the signal may be enhanced 
in certain regions).  The number and degree of these changes in response tend to be 
strongly related to the degree of sample clean-up used in the sample preparation 
method [79].  Thus “dilute and shoot” methods (i.e. methods where the sample matrix 
undergoes simple dilution with a suitable solvent, usually a buffer, before direct injection 
into the LC/MS system) will produce the largest number of response changes, followed 
by protein precipitation, with more specific clean up strategies such as solid phase 
extraction producing the fewest response changes. 
 
Use of the above methodology enables the determination of the presence, absence or 
(semi-quantitatively) the degree of suppression or enhancement of ionisation of the target 
compound(s).  This allows the decision to be made as to whether this is a significant 
enough issue to require further method development.  In order to eliminate or at least 
control such matrix effects the principal choices for method adjustment are enhanced 
sample clean up [80]; alteration to chromatography, to separate the interfering species in 
the matrix from the analytes of interest  [81]; and the use of an effective, ideally 
radiolabelled, internal standard. 
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Although it has been shown that there are significant differences in matrix effects 
between the two most common methods of ionisation in LC-MS/MS, i.e. electrospray and 
atmospheric pressure chemical ionisation [78, 82], changing mode of ionisation in order 
to reduce or eliminate matrix effects does not seem to be as widespread as would be 
expected [83, 84]. 
 
An investigation to establish a robust method for the determination of a  new drug 
candidate  in human urine was required. During the course of the method validation 
matrix effects were initially evaluated as required by regulatory guidelines [74]; however 
some limitations of the most common method for evaluating matrix effects were 
observed and further work was required to eliminate the problems identified.  Building on 
previous experience it was decided to investigate whether changing the mode of 
ionisation would reduce the level of ion suppression encountered to an acceptable level 
(i.e. to have a low enough effect to enable the “matrix effect” samples to pass the 
acceptance criteria as required by the regulations being followed). 
 
2.1.2    Experimental 
 
2.1.2.1 Materials 
 
The new drug candidate (target compound) and its primary metabolite were supplied by 
the Sponsor, the internal standard was supplied by Sigma-Aldrich (Poole, Dorset, UK).  
All reagents were of analytical grade and were supplied by Fisher Scientific UK 45 
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(Loughborough, Leicestershire, UK).  A Hypersil BDS Cyano column (50 x 4.6 mm, 
5 µm) was supplied by Thermo Electron Corporation (Basingstoke, Hampshire, UK).  
Plasma was supplied by B&K Universal (Aldbrough, Hull, UK).  Urine was supplied 
in-house and 96-well mixed-mode solid phase extraction plates containing HCX-3 were 
supplied by Argonaut (Hengoed, Glamorgam, UK). 
 
2.1.2.2 Instrumentation 
 
The system used for this work consisted of a PE Series 200 Micro-pump (Perkin Elmer, 
Thornhill, Ontario, Canada), an online DGU-14A degasser (Shimadzu, Kyoto, Japan), 
and a PE Series 200 Autosampler (Perkin Elmer, Thornhill, Ontario, Canada) connected 
to a Perkin Elmer API 4000 triple quadrupole mass spectrometer.   Chromatographic 
system control, data acquisition and analysis were performed by means of Analyst 
software version 1.2 (Applied Biosystems – MDS Pharma, UK). 
 
2.1.2.3 Chromatographic Conditions 
 
The target analyte, which was  a basic and relatively non-polar drug undergoing 
investigation for a novel (and currently confidential) use, its principal metabolite (which 
was a demethylated version of the parent and is therefore more polar than the parent) and 
the internal standard, were separated from matrix components using a Hypersil Cyano 
50 x 4.6 mm, 5 µm analytical column.  The mobile phase was acetonitrile - ammonium 
acetate (10 mM; pH 4) (35:65, v/v) (pH adjusted using acetic acid), delivered at a rate of 46 
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1.0 mL.min
-1 through the analytical column.  The retention times were approximately 1.5 
min for the target analyte, 1.3 min for the principal metabolite and 3 min for the internal 
standard. 
 
2.1.2.4   Sample Preparation 
 
A 250 µL sample was added to a polypropylene tube.  Twenty microlitres of working 
internal standard solution were added to each sample except the blanks.    The samples 
were then buffered with 1.0 mL of ammonium acetate (50 mM; pH 6), vortex mixed and 
then centrifuged. 
 
An Isolute HCX-3 solid phase extraction plate was conditioned using 1 mL methanol, 
and then equilibrated using 1.0 mL of ammonium acetate (50 mM; pH 6).  The samples 
were then added to the plate and a very low vacuum applied to slowly load the sorbent 
material.  The plate was then washed sequentially with 1 mL of ammonium acetate (50 
mM; pH 6), 1 mL of acetic acid (1 M) and 1 mL of methanol and then dried.  The 
samples were eluted into a polypropylene collection plate using 400 µL of ammonia - 
methanol (5:95, v/v) and then evaporated to dryness under nitrogen at 40°C.  The residue 
was re-dissolved in 200 µL of ammonium acetate (10 mM; pH 4) – acetonitrile (50:50, 
v/v).  The plate was then sealed, vortex mixed gently and centrifuged, then submitted for 
LC-MS/MS analysis. 
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2.1.2.5   Mass Spectrometric Detection – Starting Conditions 
 
A Perkin Elmer API 4000 triple quadrupole mass spectrometer was used in positive ion, 
multiple reaction monitoring mode using a pneumatically and thermally assisted 
electrospray interface (TurboIonSpray) with the drying gas at 450°C.  The mass 
spectrometer voltage settings i.e. the source voltage and the voltage at the interface and at 
all stages of the ion optics, were optimised for the target analyte, its principal metabolite 
and the internal standard. 
 
2.1.2.6   Post-Column Infusion for Assessment of Matrix-Related Modification 
of Ionisation 
 
 A solution containing the target analyte, its principal metabolite and the internal standard 
was added to the eluent from the analytical column via an infusion pump, which was 
connected to a flow splitter (Figure 2.3), while the mass spectrometer was scanning the 
selected ion transitions for the three analytes. 
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Figure 2.3  System configuration for post column infusion system.  HPLC  system PE 
Sciex API 4000 and PE Series 200 pumps.  Column Hypersil Cyano 50 x 4.6 mm, 5 µm 
particles.  Mobile phase acetonitrile - ammonium acetate (10 mM; pH 4) (35:63, v/v), 
flow rate 1 mL.min
-1.  The analyte or metabolite was added to the system by infusion of a 
1 µg mL
-1 solution at approximately 10 µL.min
-1 (i.e. approximately 100 ng min
-1). 
 
2.1.3    Results and Discussion 
 
The method described had been validated (by the author) for the same analytes in human 
plasma, using TurboIonSpray ionisation.  The same method was applied to human urine 
and during development it was initially shown that there were no significant matrix 
effects present.  However although this was performed using the almost ubiquitous 
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method of post-column infusion of the analytes of interest with injected matrix blanks, 
there were subsequently major problems within the validation process. 
 
During method development prior to formal validation, the modification of ionisation 
experiment  had taken  the standard form of post-column infusion of the analytes of 
interest, with several injected matrix blanks.  These injections suggested that the regions 
of suppression of ionisation were separated from the analyte retention times and that 
matrix-related modification of ionisation was therefore not a problem with this method 
(Figures 2.4 and 2.5). 50 
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Figure 2.4  Ion suppression profile for matrix blank 1 (target analyte) using 
TurboIonSpray.  HPLC system: PE Sciex API 4000 and PE Series 200 pumps, SIM for 
the target analyte.  Column Hypersil Cyano 50 x 4.6 mm, 5 µm particles.  Mobile phase 
acetonitrile - ammonium acetate (10 mM; pH 4) (35:65, v/v), flow rate 1 mL.min
-1.  The 
target analyte was added to the system by infusion at approximately 10 µL.min
-1 using the 
set-up illustrated in Figure 2.3  and  matrix blank  1  was injected (red).  This has been 
superimposed over an extracted calibration standard (blue) to illustrate the analyte retention 
time.  The infused line has levelled off (after initially dropping around the column dead 
volume at 0.5 min, where poorly retained polar matrix components elute); therefore no ion 
suppression would be expected at the analyte retention time. 
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Figure  2.5  Ion suppression profile for matrix blank 1 (principal metabolite) using 
TurboIonSpray.  HPLC system:  PE Sciex API 4000 and PE Series 200 pumps, SIM for 
the target metabolite.  Column Hypersil Cyano 50 x 4.6 mm, 5 µm particles.  Mobile phase 
acetonitrile - ammonium acetate (10 mM; pH 4) (35:65, v/v), flow rate 1 mL.min
-1.  The 
metabolite was added to the system by infusion at approximately 10 µL.min
-1 using the 
set-up illustrated in Figure 2.3  and  matrix blank 1  was injected (red).  This has been 
superimposed over an extracted calibration standard (blue) to illustrate the analyte retention 
time.  The infused line has levelled off (after initially dropping around the column dead 
volume at 0.5 min, where poorly retained polar matrix components elute); therefore no ion 
suppression would be expected at the metabolite retention time. 
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However, as part of the formal validation six individual matrices were spiked at 
concentrations at the LLOQ and at a mid-calibration level and prepared according to the 
method.  It was found that two of these matrices (here numbered 4 and 6 in Table 2.1) 
provided results that were outside the required acceptance criteria for the  principal 
metabolite, in that due to ion suppression these two matrices produced extremely low 
accuracies, which resulted in the overall accuracy and precision (measured by coefficient 
of variation) being outside the required range at each concentration of 85-115% for 
accuracy and ≤15% for precision. 
 
Table 2.1  Accuracy and precision for primary metabolite of individual matrix effect 
samples analysed using TurboIonSpray ionisation. 
 
Nominal 
concentration 
(ng/mL)
Control matrix 
ID
Observed 
concentration 
(ng/mL)
Accuracy 
(%)
Mean 
accuracy 
(%)
Coefficient of 
variation (%)
n
1 0.106 106.0
2 0.0899 89.9
3 0.0875 87.5
4 0.0236 23.6
5 0.105 105.0
6 0.0683 68.3
1 26.6 106.4
2 26.7 106.8
3 26.0 104.0
4 13.2 52.8
5 25.5 102.0
6 19.1 76.4
0.100 80.1 38.6 6
6 91.4 24.2 25.0
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Although the target analyte had provided acceptable results which suggested that the 
sample preparation was performed correctly, in order to rule out any analytical errors in 
the preparation of the matrix effect samples, a further run was performed, using the same 
six matrices, but with three replicates of each matrix at each concentration.  Each of the 
three replicates was distributed through the run, i.e. one near the start, one near the 
middle and one near the end of the run. 
 
These results confirmed the original results (Table 2.2), i.e. there were differences in 
response between several of the individuals investigated, the agreement of the replicates 
for each individual being satisfactory. 
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Table 2.2  Accuracy and precision for primary metabolite of multiple replicates of 
individual matrix effect samples analysed using TurboIonSpray ionisation. 
 
Nominal 
concentration 
(ng/mL)
Control matrix 
ID
Observed 
concentration 
(ng/mL)
Accuracy 
(%)
Mean 
accuracy 
(%)
Coefficient of 
variation (%)
n
0.100 1 0.107 107.0
0.0893 89.3
0.0892 89.2
2 0.0903 90.3
0.0918 91.8
0.0877 87.7
3 0.0850 85.0
0.0868 86.8
0.0903 90.3
4 0.0275 27.5
0.0321 32.1
0.0243 24.3
5 0.100 100.0
0.0989 98.9
0.0941 94.1
6 0.0488 48.8
0.0588 58.8
0.0457 45.7
25.0 1 24.8 99.2
26.5 106.0
25.4 101.6
2 26.0 104.0
27.1 108.4
27.2 108.8
3 26.7 106.8
26.3 105.2
24.9 99.6
4 17.0 68.0
16.4 65.6
16.5 66.0
5 26.8 107.2
25.4 101.6
25.1 100.4
6 20.0 80.0
20.1 80.4
20.8 83.2
1.9
103.1 3.5
81.2 2.1
102.3 3.4
107.1 2.5
3
3
3
3
51.1 13.4
3
3
3
3
3
3
28.0 14.0
97.7 3.2
89.9 2.3
87.4 3.1
95.2 10.8
3
3
103.9 3.6
66.5
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Accordingly it was determined that the original post-column infusion experiment should 
be revisited. 
 
The six individual matrices were extracted according to the method detailed above and 
were then injected onto the chromatographic system with the analytes infused 
post-column, as illustrated in Figure 2.3.  The first matrix was the one that had been used 
for the calibration standards and quality control samples – all of which had originally 
provided extremely accurate results during the validation.  This again confirmed that 
there was no matrix effect present for this individual matrix.  However as is indicated by 
the specimen suppression profiles illustrated in Figures 2.6 - 2.11, there was a huge 
amount of inter-individual variation in the suppression profile seen using this method.  In 
particular, the region of suppression in matrix 4 is highlighted, thereby confirming the 
reason for the low accuracies detected for this individual matrix.  For this matrix it is 
illustrated that the target analyte was eluting just after a significant suppression region 
(Figure 2.10), but the principal metabolite was eluting on top of a region with significant 
ion suppression (Figure 2.11). 
 
These results illustrated the need to investigate a number of individual sources of matrix 
to determine the presence/degree of matrix related modification of ionisation. 56 
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Figure  2.6  Ion  suppression profile for matrix blank 2 (target analyte) using 
TurboIonSpray.  HPLC system:  PE Sciex API 4000 and PE Series 200 pumps, SIM for 
the target analyte.  Column Hypersil Cyano 50 x 4.6 mm, 5 µm particles.  Mobile phase 
acetonitrile - ammonium acetate (10 mM; pH 4) (35:65, v/v), flow rate 1 mL.min
-1.  The 
target analyte was added to the system by infusion at approximately 10 µL.min
-1 using the 
set-up illustrated in Figure 2.3  and matrix blank 2 was injected (red).  This has been 
superimposed over an extracted calibration standard (blue) to illustrate the analyte retention 
time.  The infused line has levelled off (after initially dropping around the column dead 
volume at 0.5 min, where poorly retained polar matrix components elute); therefore no ion 
suppression would be expected at the analyte retention time. 
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Figure  2.7  Ion suppression profile for matrix blank 2 (principal metabolite) using 
TurboIonSpray.  HPLC system: PE Sciex API 4000 and PE Series 200 pumps, SIM for the 
principal metabolite.  Column Hypersil Cyano 50 x 4.6 mm, 5 um particles.  Mobile phase 
acetonitrile - ammonium acetate (10 mM; pH 4) (35:65, v/v), flow rate 1 mL.min
-1.  The 
principal metabolite was added to the system by infusion at approximately 10 µL.min
-1 
using the set-up illustrated in Figure 2.3 and matrix blank 2 was injected (red).  This has 
been superimposed over an extracted calibration standard (blue) to illustrate the analyte 
retention time.  The infused line has levelled off (just) before the metabolite retention time 
(after initially dropping around the column dead volume at 0.5 min, where poorly retained 
polar matrix components elute); therefore little or no ion suppression would be expected at 
the metabolite retention time. 
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Figure  2.8  Ion suppression profile for matrix blank 3 (target analyte) using 
TurboIonSpray.  HPLC system:  PE Sciex API 4000 and PE Series 200 pumps, SIM for 
the target analyte.  Column Hypersil Cyano 50 x 4.6 mm, 5 µm particles.  Mobile phase 
acetonitrile - ammonium acetate (10 mM; pH 4) (35:65, v/v), flow rate 1 mL.min
-1.  The 
target analyte was added to the system by infusion at approximately 10 µL.min
-1 using the 
set-up illustrated in  Figure 2.3  and matrix blank 3 was injected (red).  This has been 
superimposed over an extracted calibration standard (blue) to illustrate the analyte retention 
time.  The infused line has levelled off (after initially dropping around the column dead 
volume at 0.5 min, where poorly retained polar matrix components elute); therefore no ion 
suppression would be expected at the analyte retention time. 
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Figure  2.9  Ion suppression profile for matrix blank 3 (principal metabolite) using 
TurboIonSpray.  HPLC system:  PE Sciex API 4000 and PE Series 200 pumps, SIM for the 
principal metabolite.  Column Hypersil Cyano 50 x 4.6 mm, 5 µm particles.  Mobile phase 
acetonitrile - ammonium acetate (10 mM; pH 4) (35:65, v/v), flow rate 1 mL.min
-1.  The 
principal metabolite was added to the system by infusion at approximately 10 µL.min
-1 
using the set-up illustrated in Figure 2.3 and matrix blank 3 was injected (red).  This has 
been superimposed over an extracted calibration standard (blue) to illustrate the analyte 
retention time.  The infused line has levelled off (just) before the metabolite retention time 
(after initially dropping around the column dead volume at 0.5 min, where poorly retained 
polar matrix components elute); therefore little or no ion suppression would be expected at 
the metabolite retention time. 
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Figure  2.10  Ion suppression profile for matrix blank 4 (target analyte) using 
TurboIonSpray.  HPLC system:  As Figure 2.4.  The target analyte was added to the 
system by infusion at approximately 10 µL.min
-1 using the set-up illustrated in Figure 2.3 
and matrix blank 4 was injected (red).  This has been superimposed over an extracted 
calibration standard (blue) to illustrate the analyte retention time.  The infused line has 
levelled off (after initially dropping around the column dead volume at 0.5 min, where 
poorly retained polar matrix components elute); therefore no ion suppression would be 
expected at the analyte retention time.  N.B.  Although at a retention time before the 
target analyte peak there is appreciably greater amount of suppression than for matrices 
1-3. 
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Figure  2.11  Ion suppression profile for matrix blank 4 (principal metabolite) using 
TurboIonSpray.  HPLC system:  As Figure 2.5.  The principal metabolite was added to 
the system by infusion at approximately 10 µL.min
-1 using the set-up illustrated in Figure 
2.3 and matrix blank 4 was injected (red).  This has been superimposed over an extracted 
calibration standard (blue) to illustrate the analyte retention time.  The metabolite 
retention time exactly corresponds to one of the suppression areas (at 1.4 min); therefore 
significant ion suppression is present. 
 
As the suppression regions were found all around the analytes of interest (particularly 
with “matrix 4”, it was  determined that it would be difficult to chromatographically 
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resolve this problem.  As the sample preparation method used was fairly specific, using 
mixed-mode solid phase extraction, it was determined that a different way of overcoming 
the problem was required to changing the sample preparation method. 
 
Accordingly it was decided to investigate a change of the mode of ionisation from 
TurboIonSpray to atmospheric pressure chemical ionisation (APCI).  It was expected that 
this might result in a reduction or elimination of the matrix effects observed as APCI is 
considered to be far less susceptible to matrix-related modification of ionisation than 
TurboIonSpray  [75].  The same matrix extracts that were used for the experiment 
illustrated in Figures 2.6  through  2.11  were used in a similar post-column infusion 
experiment, but with the mass spectrometer in APCI mode.  This confirmed that there 
was far less modification of ionisation due to matrix in general and that the effect on the 
analytes of interest could be eliminated by this change of interface (Figures 2.12 - 2.19).  
As there was sufficient sensitivity to exceed the required limit of detection using APCI, 
this simple change of ionisation mode was used for the full validation of the analytical 
method.  The lack of matrix-related modification of ionisation is illustrated in Tables 2.3 
and 2.4, where the accuracy and precision values at each concentration are well within 
the acceptance criteria (85 - 115% for accuracy; ≤15% for precision) for each analyte (in 
contrast to the values illustrated in Table 2.1 obtained when analysing similar samples 
using TurboIonSpray as the mode of ionisation. 63 
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Figure 2.12  Ion suppression profile for matrix blank 1 (target analyte) using APCI.  
HPLC system:  As Figure 2.4.  The target analyte was added to the system by infusion at 
approximately 10 µL.min
-1 using the set-up illustrated in Figure 2.3 and matrix blank 1 
was injected (red).  This has been superimposed over an extracted calibration standard 
(blue) to illustrate the analyte retention time.  The infused line has levelled off (after 
initially dropping around the column dead volume at 0.5 min, where poorly retained polar 
matrix components elute); therefore no ion suppression would be expected at the analyte 
retention time.  N.B.  The region of suppression occurring at around 0.5 min is 
significantly less pronounced than for the same matrix using TurboIonSpray. 
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Figure 2.13  Ion suppression profile for matrix blank 1 (principal metabolite) using 
APCI.  HPLC system:  As Figure 2.5.  The principal metabolite was added to the system 
by infusion at approximately 10 µL.min
-1 using the set-up illustrated in Figure 2.3 and 
matrix blank 1 was injected (red).  This has been superimposed over an extracted 
calibration standard (blue) to illustrate the analyte retention time.  The infused line has 
levelled off (after initially dropping around the column dead volume at 0.5 min, where 
poorly retained polar matrix components elute); therefore no ion suppression would be 
expected at the metabolite retention time.  N.B.  The region of suppression occurring at 
around 0.5 min is significantly less pronounced than for the same matrix using 
TurboIonSpray. 
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Figure 2.14  Ion suppression profile for matrix blank 2 (target analyte) using APCI.  
HPLC system:  As Figure 2.4.  The target analyte was added to the system by infusion at 
approximately 10 µL.min
-1 using the set-up illustrated in Figure 2.3 and matrix blank 2 
was injected (red).  This has been superimposed over an extracted calibration standard 
(blue) to illustrate the analyte retention time.  The infused line has levelled off (after 
initially dropping around the column dead volume at 0.5 min, where poorly retained polar 
matrix components elute); therefore no ion suppression would be expected at the analyte 
retention time.  N.B.  The region of suppression occurring at around 0.5 min is 
significantly less pronounced than for the same matrix using TurboIonSpray. 
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Figure 2.15  Ion suppression profile for matrix blank 2 (principal metabolite) using 
APCI.  HPLC system:  As Figure 2.5.  The principal metabolite was added to the system 
by infusion at approximately 10 µL.min
-1 using the set-up illustrated in Figure 2.3 and 
matrix blank 2 was injected (red).  This has been superimposed over an extracted 
calibration standard (blue) to illustrate the metabolite retention time.  The infused line has 
levelled off (after initially dropping around the column dead volume at 0.5 min, where 
poorly retained polar matrix components elute); therefore no ion suppression would be 
expected at the metabolite retention time.  N.B.  The region of suppression occurring at 
around 0.5 min is significantly less pronounced than for the same matrix using 
TurboIonSpray. 
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Figure 2.16  Ion suppression profile for matrix blank 3 (target analyte) using APCI.  
HPLC system:  As Figure 2.4.  The target analyte was added to the system by infusion at 
approximately 10 µL.min
-1 using the set-up illustrated in Figure 2.3 and matrix blank 3 
was injected (red).  This has been superimposed over an extracted calibration standard 
(blue) to illustrate the analyte retention time.  The infused line has levelled off (after 
initially dropping around the column dead volume at 0.5 min, where poorly retained polar 
matrix components elute); therefore no ion suppression would be expected at the analyte 
retention time.  N.B.  The region of suppression occurring at around 0.5 min is 
significantly less pronounced than for the same matrix using TurboIonSpray. 
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Figure 2.17  Ion suppression profile for matrix blank 3 (principal metabolite) using 
APCI.  HPLC system:  As Figure 2.5.  The principal metabolite was added to the system 
by infusion at approximately 10 µL.min
-1 using the set-up illustrated in Figure 2.3 and 
matrix blank 3 was injected (red).  This has been superimposed over an extracted 
calibration standard (blue) to illustrate the metabolite retention time.  The infused line has 
levelled off (after initially dropping around the column dead volume at 0.5 min, where 
poorly retained polar matrix components elute); therefore no ion suppression would be 
expected at the metabolite retention time.  N.B.  The region of suppression occurring at 
around 0.5 min is significantly less pronounced than for the same matrix using 
TurboIonSpray. 
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Figure 2.18  Ion suppression profile for matrix blank 4 (target analyte) using APCI.  
HPLC system:  As Figure 2.4.  The target analyte was added to the system by infusion at 
approximately 10 µL.min
-1 using the set-up illustrated in Figure 2.3 and matrix blank 4 
was injected (red).  This has been superimposed over an extracted calibration standard 
(blue) to illustrate the analyte retention time.  The infused line has levelled off (after 
initially dropping around the column dead volume at 0.5 min, where poorly retained polar 
matrix components elute); therefore no ion suppression would be expected at the analyte 
retention time.  N.B.  The region of suppression occurring at around 0.5 min is 
significantly less pronounced than for the same matrix using TurboIonSpray. 
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Figure 2.19  Ion suppression profile for matrix blank 4 (principal metabolite) using 
APCI.  HPLC system:  As Figure 2.4.  The principal metabolite was added to the system 
by infusion at approximately 10 µL.min
-1 using the set-up illustrated in Figure 2.3 and 
matrix blank 1 was injected (red).  This has been superimposed over an extracted 
calibration standard (blue) to illustrate the metabolite retention time.  The infused line has 
levelled off (after initially dropping around the column dead volume at 0.5 min, where 
poorly retained polar matrix components elute); therefore no ion suppression would be 
expected at the metabolite retention time.  In this example the region of suppression that 
directly coincided with the analyte retention time when using TurboIonSpray has been 
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completely eliminated.  Only a small region of suppression (occurring at around 0.5 min) 
is present. 
 
Table 2.3  Accuracy and precision of individual matrix effect samples using APCI 
(target analyte). 
Nominal 
concentration 
(ng/mL)
Control matrix 
ID
Observed 
concentration 
(ng/mL)
Accuracy 
(%)
Mean 
accuracy 
(%)
Coefficient of 
variation (%)
n
1 0.0917 91.7
2 0.113 113.0
3 0.103 103.0
4 0.105 105.0
5 0.109 109.0
6 0.103 103.0
1 23.7 94.8
2 23.6 94.4
3 23.6 94.4
4 25.7 102.8
5 26.9 107.6
6 24.2 96.8
6 98.5 5.6
0.100 104.1 6.9 6
25.0
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Table 2.4  Accuracy and precision of individual matrix effect samples using APCI 
(principal metabolite). 
Nominal 
concentration 
(ng/mL)
Control matrix 
ID
Observed 
concentration 
(ng/mL)
Accuracy 
(%)
Mean 
accuracy 
(%)
Coefficient of 
variation (%)
n
1 0.0904 91.7
2 0.0905 90.5
3 0.103 103.0
4 0.107 105.0
5 0.105 109.0
6 0.103 103.0
1 21.9 87.6
2 23.6 94.4
3 22.9 91.6
4 25.0 100.0
5 26.2 104.8
6 23.5 94.0
6 95.4 6.4
0.100 100.4 7.4 6
25.0
 
 
2.1.4    Conclusions 
 
There are several accepted ways of investigating matrix effects, but a full understanding 
of the techniques being employed is essential if significant findings are not to be ignored.  
It has been demonstrated clearly by this illustrative example that the ubiquitous technique 
of determining the effect on a matrix blank of post-column infusion of analyte has 
limitations, if an understanding of the variability of the matrix is not considered.  In 
general on the basis of this example, it is suggested that the matrix effect trial using 
post-column infusion should be performed for at least six separate sources of individual 
matrix and it should be performed for all analytes being investigated, including the 
internal standard. 73 
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As urine varies extremely widely in both concentration and content  [85,  86]  it is 
particularly important to perform such trials on a range of individuals, in order to avoid 
erroneous conclusions about the absence of analytical issues. 
 
Amongst the strategies normally employed to minimise matrix-related modification of 
ionisation is the use of stable isotopically-labelled internal standards.  As well as the 
difficulties associated with obtaining such standards, particularly at the early stages of 
drug development, there are other problems associated with this approach.  For many 
assays there are several target analytes (e.g. a compound and its metabolites) and the 
labelled internal standard may only be available for one of these [73].  Another problem 
can be that the internal standard will actually mask the problem at an early stage, with the 
suppression of ionisation not immediately apparent [87].  This may become a more 
significant problem when samples are analysed from clinical studies, where the variation 
between matrices from the “perfect” matrix that tends to be used for validation studies 
may result in erroneous results.  Finally, if the matrix effect occurs at the retention time 
of the internal standard, the ratio of analyte : internal standard may be affected in 
different ways at different concentrations. 
 
Each of the problems listed for stable isotopically-labelled internal standards are 
potentially magnified when using structural analogues as internal standard.  It is therefore 
essential to perform the suppression investigation performed in this illustrative example 
on any internal standard which is a structural analogue of the target analyte(s).  In the 74 
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illustrated example a structural analogue was in fact used as internal standard for both 
target analyte and principal metabolite.  This analogue had a later retention time than 
either the target analyte or principal metabolite (approximately 2.5 min) and investigation 
suggested no region of suppression near the internal standard retention time. 
 
The phenomenon of matrix-related modification of ionisation is a well established one.  
Although this problem was well documented before the reported work, the above 
example represents very good illustrative evidence of the possible extent of the problem, 
and the limitations of the “standard” method for overcoming it.  This  example has 
provided a good example which demonstrates the effectiveness of the option on changing 
the mode of ionisation. 
 
In summary of the strategies discussed in this chapter, matrix effects can often be both 
greater and of more complexity than first envisaged, but with due care and attention and 
carefully thought out development protocols they can be overcome with relative ease, 
without resorting to stable-isotopically labelled internal standards, an option that will not 
always be available anyway. 75 
 
 
 
Chapter 3 
 
 
Post-Column Modification of Mobile Phase 
 
 
 
 
3.1  Introduction 
Although LC-API/MS is the dominant technique used for drug bioanalysis  [16], the 
determination of enantiomers in biological fluids is one case where the application of 
LC-API/MS is not always straightforward.  This is because for many methods for the 
separation of enantiomers the ideal chromatographic conditions are not readily 
compatible with mass spectrometric detection [88, 89].  For example, in the vast majority 
of chiral separations carried out on the most popular commercially available LC chiral 
stationary phases (CSP) i.e. derivatised polysaccharides, the mobile phase used, often 
n-hexane – propan-2-ol, with a basic or acidic additive, is non-aqueous [90] and does not 
lend itself readily to API/MS detection.  Similarly, the ‘polar-organic’ mobile phases 
frequently used with cyclodextrin or macrocyclic antibiotic CSP [91] are usually not 
API/MS-friendly. 
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One solution to this type of problem is to ‘re-invent’ the chiral chromatography and 
indeed this approach was adopted for chiral separations which had been carried out using 
the polar-organic mode by developing a polar-ionic
 separation [92] in which the ratio of 
amine to acid mobile phase modifier was adjusted so that atmospheric pressure ionisation 
became possible and there was still a chiral separation.  Clearly though, it would be 
preferable to be able to proceed with pre-existing optimised conditions for the chiral 
separation.  This is especially the case given the current scenario in which, almost 
exclusively, new chiral drugs are developed in a single enantiomer form [93].  In this 
situation enantioselective drug bioanalysis may be carried out strategically, rather than 
routinely in the Discovery phase, when it is being ascertained which enantiomer is the 
most suitable to develop, and during the Development phases, when checks for in vivo 
racemisation or chiral inversion are being made.  It is therefore often difficult to justify 
more extensive method development, or in many cases there may be no choice about the 
chiral separation - there may be only one optimised separation, with no option to modify 
the mobile phase.  Accordingly it was sought here to explore the possibility of adopting a 
less elegant, but easier to develop, approach of persisting with the non-API/MS-friendly 
mobile phase used for the chiral separation and employing post-column solvent addition 
to bring about conditions suitable for more optimal atmospheric pressure ionisation.  This 
was originally investigated  in a preliminary study  for a number of dihydropyridine 
calcium channel blockers and fully validated for the specimen dihydropyridine felodipine 
(Figure 3.1), and has now been investigated for the detection of the enantiomers of a 
number of chiral drugs from a range of therapeutic categories.  77 
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Figure 3.1  Structures of a Generic Dihydropyridine Calcium Channel Blocker 
and Felodipine.  The “R” groups vary between dihydropyridines. 
 
3.2  Experimental 
3.2.1  Materials 
 
A column packed with AGP-CSP (Chiral AGP, 100 mm x 4.0 mm, 5 µm) was supplied 
by Chromtech Ltd. (Congleton, Cheshire, UK).  A column packed with a 
β-cyclodextrin-immobilised stationary phase (Cyclobond I, 250 mm x 4.0 mm, 5 µm) 
was supplied by ASTEC (Congleton, Cheshire, UK).  Analytical grade reagents were 
supplied by Fisher Scientific (Loughborough, Leicestershire, UK).  All compounds were 
supplied by Sigma Aldrich (Poole, Dorset, UK). 
 
3.2.2  Instrumentation 
 
The system used for this work consisted of a PE Series 200 Micro-pump (Perkin Elmer, 
Thornhill, Ontario, Canada), an online DGU-14A degasser (Shimadzu, Kyoto, Japan), 78 
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and a PE Series 200 Autosampler (Perkin Elmer, Thornhill, Ontario, Canada) connected 
to a Perkin Elmer API 3000 triple quadrupole mass spectrometer.   Chromatographic 
system control, data acquisition and analysis were performed by means of Analyst 
software version 1.2 (Applied Biosystems – MDS Pharma, UK). 
 
3.2.3  Chromatographic Conditions 
 
The mobile phase for optimum enantiomeric separation was taken from literature 
methods and varied from  0-16% organic (0%  terbutaline
  [94], ephedrine [95], 0.2% 
ondansetron [96], 0.5% propranolol [97], 1% pheniramine [98], 1.3% terfenadine [99],  
2% brompheniramine [100], 5% mianserin [101], mexiletine [102]  16% organic 
(ketamine  [103]) delivered at a rate of 1.0 mL.min
-1  through the analytical column.  
Conditions for enantiomeric resolution were again  confirmed experimentally prior to 
investigation of post-column modification of ionisation. 
 
3.2.4  Tandem Mass Spectrometric Detection 
 
A Perkin Elmer API 3000 triple quadrupole mass spectrometer was used in positive ion, 
multiple reaction monitoring mode using a pneumatically and thermally assisted 
electrospray interface (TurboIonSpray) with the drying gas set at 475°C.  The mass 
spectrometer voltage settings were optimised for each analyte being investigated. 
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The mobile phase was introduced at 1.0 mL.min
-1 directly through the analytical column.  
A second pump was connected to the chromatographic system post column, via a tee 
piece, which allowed the introduction of acetonitrile to enable mixing with the column 
eluent.  Following this tee piece a further tee was connected to act as a split to allow some 
of the combined mobile phase and acetonitrile to flow to waste, thereby optimising the 
flow to the mass spectrometer (Figure 3.2). 
 
Figure 3.2  LC configuration used for post-column optimisation.  Acetonitrile is 
added via a tee-piece (“mixing tee”) after the analytical column, which results in a large 
total flow rate of greater than 1.0 mL.min
-1, which is split to waste, using a second 
tee-piece (“split tee”). 
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3.3  Results and Discussion 
 
Optimal enantioseparation for a range of compounds investigated used predominantly 
aqueous mobile phases (with less than 10% v/v organic modifier), when using mobile 
phases that are suitable for API/MS.  As one of the principal determinants for sensitivity 
in the mass spectrometer is ion evaporation [104], these mobile phases are not well suited 
for high sensitivity.  In order to overcome the problems associated with poor evaporation, 
the effect of post-column addition of organic modifier on sensitivity was investigated. 
 
3.3.1    Percentage of Organic Modifier 
 
The amount of acetonitrile added post-column was gradually increased, without varying 
total flow rate, sample concentration and volume.  This was achieved by increasing the 
amount of acetonitrile flowing through the mixing tee, whilst simultaneously reducing the 
final volume reaching the mass spectrometer using the split tee (as illustrated in 
Figure 3.2).  The peak area obtained against the concentration of acetonitrile in the final 
mobile phase arriving at the MS interface is shown in Table 3.1.  Due to the system used 
for adjusting the percentage of organic modifier, the amount of analyte reaching the mass 
spectrometer is being reduced; therefore the overall increase in sensitivity reported is 
actually significantly smaller than the absolute increase obtained if measured per unit 
mass of analyte reaching the mass spectrometer (N.B. the flow to the mass spectrometer 
was kept constant, by increasing the split to waste with increased flow rate). 
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Table 3.1  Peak area in relation to acetonitrile concentration. 
Compound  Average Response (Mean of 3 replicate injections) 
   5%  10%  15%  20%  25%  30%  40%  50%  60%  70%  80%  90%  95% 
                              
Brompheniramine  8166  9426  9875  9723  11322  12045  13782  15128  17099  19722  22412  27196  28884 
                              
Pheniramine  201707  202525  227847  218980  235864  205069  288481  311377  384474  458184  560267  699101  839527 
                              
Ephedrine  117405  111444  113028  129569  149841  182200  203400  279685  356394  429386  550363  714273  806965 
                              
Ketamine  1961  2068  2291  2489  2425  2707  3181  3561  4147  4756  5540  6764  7272 
                              
Mexiletine  836  892  919  1242  1370  1713  1993  2678  3679  4868  6056  7619  8364 
                              
Mianserin  7787  8756  11133  12472  14526  15842  18444  21158  24004  29088  34008  41422  43581 
                              
Ondansetron  6299  6961  7839  8174  8109  8897  9790  9940  11240  12490  14103  15077  13561 
                              
Propranolol  1233  1408  1618  1765  2084  2252  2706  3461  4398  5432  6986  9313  10669 
                              
Terbutaline  4389  4351  5245  6156  7194  7458  9540  11556  14518  18627  23134  28781  29323 
                              
Terfenadine  46196  74638  N/A  200712  N/A  346137  439655  571733  756474  1007148  1500840  2651602     N/A 
                                         
N/A = not applicable – not investigated at the stated acetonitrile concentration 
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Figure 3.3  Structures of analytes investigated using post-column modification of mobile phase. 83 
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Rather than tabulate and graph with multiple scales, due to the differences in response for 
the various analytes, a correction factor was applied for each analyte to bring the average 
response with 5% acetonitrile to a similar value.  This involved division of the observed 
response by the following factors:  4, 100, 50, 600, 0.4, 130, 3, 140, 2 and 20 for 
brompheniramine, pheniramine, ephedrine, ketamine, mexiletine, mianserin, ondansetron, 
propranolol, terbutaline and terfenadine, respectively.  These normalised responses are 
shown in Table 3.2. 
 
These changes in response are better illustrated in Figure 3.4.  The response for 
terfenadine showed a far greater increase with increase in organic modifier concentration 
than any of the other compounds investigated, possibly due to it being by far the most 
non-polar of the compounds.  A further graph with terfenadine removed is presented in 
Figure 3.5 to illustrate the general trend in more detail. 
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Table 3.2  A comparison of the change in response with increased acetonitrile concentration. 
Compound  Average Response (Mean of 3 replicate injections)  Maximum 
increase 
(x lowest)     5%  10%  15%  20%  25%  30%  40%  50%  60%  70%  80%  90%  95% 
                                 
Brompheniramine  2042  2357  2469  2431  2831  3011  3446  3782  4275  4931  5603  6799  7221  3.5 
                                 
Pheniramine  2017  2025  2278  2190  2359  2051  2885  3114  3845  4582  5603  6991  8395  4.2 
                                 
Ephedrine  2348  2229  2261  2591  2997  3644  4068  5594  7128  8588  11007  14285  16139  6.9 
                                 
Ketamine  1961  2068  2291  2489  2425  2707  3181  3561  4147  4756  5540  6764  7272  3.7 
   2383  2680  N/A  3359  N/A  4368  5638  6880  8320  10052  11966  13766  N/A   5.8 
 
Mexiletine  2089  2230  2297  3105  3425  4282  4984  6696  9198  12170  15141  19048  20909  10.0 
                                 
Mianserin  2049  2304  2930  3282  3823  4169  4854  5568  6317  7655  8950  10901  11469  5.6 
   2048  2787  N/A  3949  N/A  5161  6589  8161  10115  12630  15897  21140   N/A  10.3 
 
Ondansetron  2100  2320  2613  2725  2703  2966  3263  3313  3747  4163  4701  5026  4520  2.2 
                                 
Propranolol  2096  2394  2751  3000  3542  3828  4601  5884  7477  9234  11876  15831  18137  8.7 
   2024  2390  N/A  2967  N/A  3888  5055  6442  8426  10863  14432  21140  N/A   10.4 
 
Terbutaline  2195  2176  2622  3078  3597  3729  4770  5778  7259  9314  11567  14391  14662  6.7 
                                 
Terfenadine  2310  3732  N/A  10036  N/A  17307  21983  28587  37824  50357  75042  132580   N/A  57.4 
                                            
N/A = not applicable – not investigated at the stated acetonitrile concentration 
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Figure 3.4  Response of analyte against percentage of organic in mobile phase at mass spectrometer.  In all cases the response 
increased significantly with increasing concentration of the organic modifier. 86 
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Figure 3.5  Response of analyte against percentage of organic in mobile phase at mass spectrometer, excluding terfenadine.  
Excluding terfenadine, which had a far larger change in response than the other compounds investigated, this highlights that there was 
an increase in response from two-fold to about an order of magnitude.  When dealing with difficult to achieve limits of detection this 
can be the difference between meeting the required range and failing to do so. 87 
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3.3.2    Split Ratio 
 
In addition to the volatility of the mobile phase reaching the MS interface, as controlled 
by the proportion of acetonitrile incorporated, the effect of flowrate of mobile phase 
reaching the interface was also examined. 
 
The effect of flowrate at the MS interface on peak area of an example compound 
(felodipine) is shown in Figure 3.6.  These results were obtained using a mobile phase 
split of approximately 20% to the MS (the remainder to waste). 
 
 
Figure 3.6  Split Optimisation.  This illustrates the increase in response (peak area) for 
felodipine with increasing proportion of acetonitrile in the mobile phase that reaches the 
mass spectrometer. 88 
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Optimisation for felodipine resulted in the following conditions.  The flow rate used for 
the acetonitrile was 0.9 mL.min
-1, with the split allowing 0.2 mL.min
-1  to  the mass 
spectrometer.  This produced a final proportion of only 50% acetonitrile in the final 
eluent reaching the mass spectrometer, which was lower than the optimum observed in 
the experiment illustrated by Figure 3.6.  This was due to difficulties in the reliability of 
the mixing of the mobile phase and acetonitrile, which reduced the precision of repeated 
injections, if larger total flow rates were used. 
 
The concentration of analyte reaching the mass spectrometer is effectively being reduced 
(by the post-column addition of organic mobile phase).  However, the increase in 
sensitivity achieved using this technique more than compensated for this reduction in 
concentration. 
 
These conditions gave rise to an approximate ten-fold increase in sensitivity over the 
original conditions investigated without post-column modification of mobile phase.   
 
The degree of enhancement was investigated for a number of chiral compounds to 
determine whether the limits of detection under existing optimised conditions for 
enantioseparation could be improved to a significant (i.e. order of magnitude) degree.  In 
addition the technique has been further investigated to establish whether or not a method 
involving this post-column solvent addition would stand up to the rigours of a full 
method validation [105]. 
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For the evaluation of post-column modification of mobile phase as a generic method for 
the improvement in sensitivity for a range of analyte, the flow rate reaching the mass 
spectrometer interface was set at approximately 0.5 mL.min
-1. 
 
It was clear from the study of post-column modification that this simple method for the 
enhancement of sensitivity which had enabled the validation of a method for the 
determination of a specimen dihydropyridine [105] to rigorous internationally recognised 
standards, was likely to be applicable not only to dihydropyridines but also to a wide 
range of basic drugs. 
 
A major problem with many methods for the separation of enantiomers is that the ideal 
chromatographic conditions are not readily compatible with mass spectrometric 
detection.  This is due to the nature of the mobile phase required for optimum separations 
and is particularly true for the protein based CSPs, such as the AGP-CSP used here. 
 
 
3.4  Conclusions 
 
The approach to overcoming the problem presented here involved the post-column 
addition of an organic modifier in sufficient quantities to enhance ion evaporation.  The 
concentration of analyte reaching the mass spectrometer is effectively being reduced (by 
the post-column addition of organic mobile phase).  However the increase in sensitivity 
achieved using this technique more than compensates for this reduction in concentration. 90 
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The proportion of the organic component required for the optimum increase in sensitivity 
varies widely depending on the compound type.  This may be due to the relative affinity 
of the compounds to the droplet surface.  It is possible to further enhance sensitivity by 
the optimisation of the split ratio, which controls the flow rate of mobile phase to the 
mass spectrometer. 
 
This simple artefact enabled a ten-fold increase in sensitivity over the original conditions 
investigated without post-column modification of mobile phase to be used for the 
validation of a method for one of the analytes investigated. 
 
While there a number of interesting features of the illustrative method described, the 
main conclusions of this study are very clear.  The device of using post-column addition 
of organic solvent for chiral drug bioanalysis by LC-API/MS using highly aqueous 
mobile phases proved to be easy to set up, robust in use and led to significantly improved 
sensitivity and a rapidly developed method.  It was a very practical solution to the 
problem of poor sensitivity when using highly aqueous mobile phases in that it allowed 
previously published optimum conditions for the chiral separations to be used. 
 
Further, it would be anticipated that a similar approach could be successfully employed in 
other instances, such as when using “polar-organic” and hexane - propan-2-ol mobile 
phases mentioned in Section 3.1, of achieving chiral separations using MS-unfriendly 
mobile phases.  Indeed, at a recent UK symposium, a Pfizer speaker (P Ferguson, 91 
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Hichrom Chiral HPLC Symposium, Sandwich, 25 Sept 2006) gave a presentation of the 
use of post-column modification of mobile phase to solve a sensitivity problem in 
“straight-phase” chiral work.  This mainly used illustrative examples to show that the use 
of the post-column modification of mobile phase discussed in this chapter, works well as 
a general technique to improve sensitivity when struggling for sensitivity with other 
equally MS-unfriendly mobile phases.  92 
 
 
 
Chapter 4 
 
 
Strategies for dealing with quantitative determination of endogenous 
analytes 
 
 
 
There are a number of reasons for the requirement for a robust method for the 
determination of an endogenous analyte.  One of the principal ways of determining the 
effectiveness of a therapy can be by observing the effect of a dose of a drug substance on 
an endogenous compound in a biological system (i.e. a bio-marker [106]).  In order to do 
this effectively a method for the quantitative analysis of the bio-marker would be 
required.  Similarly bio-markers may be used as an indication of a disease state, where 
their presence/absence and concentration may provide an indication of the presence or 
progress of a disease. 
 
The main problem associated with the quantitative analysis of endogenous analytes is 
associated with the provision of “control” matrix, i.e. a supply of the matrix to be 
analysed that does not contain the analytes under investigation.  There are a number of 
strategies available to overcome this problem: 93 
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a)  The use of a “surrogate” matrix, i.e. a matrix that is as similar to the sample 
matrix as possible, but that does not contain the target analyte [107].  For example, as will 
be described in Section 4.1, the use of gelding serum for testosterone analysis.  The 
similarity of a surrogate to the sample matrix can be extremely good, but the main 
disadvantage of this approach is that there are many examples where a truly 
representative surrogate can not be obtained. 
 
b)  The use of non-matrix standards, where the calibration standards (and possibly 
quality control samples) are prepared in the injection solvent used for the analysis, 
without any matrix present at any time in the sample preparation procedure [108].  This is 
an extremely simple approach, but suffers from the difficulties associated with sample 
extraction recovery and matrix effects. 
 
c)  The adoption of the standard addition method for sample and standard 
preparation.  Using this methodology a standard solution (i.e. a solution containing a 
known concentration of the analyte) is added to the unknown solution or sample matrix 
so that the endogenous amount can be accounted for in the analysis [109].  Knowledge of 
how the response changes before and after adding the standard solution allows 
extrapolation to determine the concentration initially in the sample.  In many cases this 
can provide an excellent strategy for these analyses, as any matrix-related (extraction and 
ionisation) effects are minimised.  The main disadvantage is that the response of an 
analyte may not be linear across the entire range, particularly if the endogenous level 
selected is relatively high within the dynamic range investigated. 94 
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d)  For many matrices, e.g. plasma, charcoal-stripping may be utilised.  This involves 
many compounds within the matrix being removed by passing the matrix over charcoal 
[110].  The main disadvantages of this technique are that it can result in incomplete 
removal of the analyte and it can be an expensive and time-consuming technique. 
 
e)  The use of a surrogate analyte, where for example a deuterated version of the 
target analyte is used to generate the calibration curve (rather than as an internal standard) 
and the sample concentrations of the target analyte are read off this calibration curve 
[111].  Difficulties in obtaining pure deuterated analyte, or the preference to use the 
deuterated version of the analyte as an internal standard make this a rare strategy of 
choice. 
 
The advantages and disadvantages of these strategies may be dependent on the nature of 
the sample matrix or the nature of the target analyte.  The choice of which of these 
strategies to adopt is likely to be dependent on practicability, based on the availability of 
a suitable surrogate (matrix or analyte), though in practice, it is often based on familiarity 
with a particular solution.  All of these strategies can provide a suitable methodology for 
the preparation of a robust analytical method, but the essential thing is to prove the 
suitability of the strategy selected,  through the course of the method evaluation and 
validation. 95 
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4.1  A Method for the Determination of Clinically Suppressed Levels of 
Testosterone in Human Serum 
 
4.1.1  Introduction 
Testosterone is the principal male sex hormone, which is responsible for the growth and 
development of masculine characteristics.  It has a direct influence of the maturation of 
the male sexual organs, development of sperm within the testes, sexual drive, erectile 
function of the penis, and male secondary sexual characteristics including facial hair and 
pronounced musculature.  Testosterone is produced in the testes.  Testosterone adversely 
affects diseases of the prostate gland by  increasing the growth of carcinomas of the 
prostate. 
 
Chemical castration is a clinical aim in certain therapies, in particular therapies for the 
treatment of cancer of the prostrate gland.  Chemical castration is considered to be 
defined as a serum testosterone level of below 100  pg.mL
-1  [112, 113].  The range 
normally found in male humans is 3500-10800 pg.mL
-1 [114].  In order to monitor the 
suppressed levels of testosterone in chemically castrated males a lower  limit of 
quantification of 50 pg.mL
-1 was required. 
 
One of the major problems in measuring such low levels is obtaining “blank” serum, with 
even normal serum concentrations in female humans being 150 to 700 pg.mL
-1[115].  The 
aim of this investigation was to assess the suitability of using equine (gelding) serum  as a 
surrogate matrix to overcome the problem.   96 
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Figure 4.1.1  Structures of Testosterone and Testosterone-D3 
 
4.1.2  Experimental 
 
4.1.2.1   Materials 
 
Testosterone and testosterone-D3 were supplied by Sigma-Aldrich (Poole, Dorset, UK).  
All reagents were of analytical grade and were supplied by Fisher Scientific UK 
(Loughborough, Leicestershire, UK).  Genesis C18 columns (50 x 4.6 mm, 3 µm) were 
supplied by Grace Vydac (Carnforth, Lancashire, UK).  Equine serum was supplied by 
B&K Universal (Aldbrough, Hull, UK).  96-well solid phase extraction plates 
(Isolute C18, 2 mL, 100 mg) were supplied by Argonaut (Hengoed, Glamorgan, UK). 
 
4.1.2.2 Instrumentation 
 
The system used for this work consisted of a PE Series 200 Micro-pump (Perkin Elmer, 
Thornhill, Ontario, Canada), an online DGU-14A degasser (Shimadzu, Kyoto, Japan), 
and a PE Series 200 Autosampler (Perkin Elmer, Thornhill, Ontario, Canada) connected 97 
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to a Perkin Elmer API 3000 triple quadrupole mass spectrometer.   Chromatographic 
system control, data acquisition and analysis were performed by means of Analyst 
software version 1.2 (Applied Biosystems – MDS Pharma, UK). 
 
4.1.2.3 Chromatographic Conditions 
 
Testosterone and the internal standard, testosterone-D3  were separated from matrix 
components using a Genesis C18 50 x 4.6 mm, 3 µm analytical column.  The mobile 
phase was methanol - ammonium acetate (10 mM; pH native) (75:25, v/v), delivered at a 
rate of 1.0 mL.min
-1  through the analytical column.  The retention times were 
approximately 2.0 min for both testosterone and testosterone-D3. 
 
4.1.2.4   Sample Preparation 
 
A 500 µL sample was added to a polypropylene tube.  75 µL of acetonitrile were added 
to each sample.  These were then vortex mixed, and left to stand for 10 min.  The samples 
were then buffered with 1.0 mL ammonium acetate (10 mM; pH native), containing 
internal standard at 5 ng.mL
-1, vortex mixed and then centrifuged. 
 
An Isolute C18 solid phase extraction plate was conditioned using 1 mL methanol, and 
then equilibrated using 1.0 mL of ammonium acetate (10 mM; pH native).  The samples 
were then added to the plate and a very low vacuum applied to slowly load the sorbent 
material.  The plate was then washed with 1 mL ammonium acetate (10 mM; pH native) 98 
________________________________________________________________________ 
 
and the plate was fully dried.  The plate was then washed with 1 mL hexane and the plate 
was again fully dried.  The samples were eluted into a polypropylene collection plate 
using 2 aliquots of 800 µL methyl acetate and then evaporated to dryness under nitrogen 
at 40°C.  The residue was redissolved in 200 µL methanol - ammonium acetate (10 mM; 
pH native) (50:50, v/v).  The plate was then sealed, vortex mixed gently, centrifuged, and 
then submitted for LC-MS/MS analysis. 
 
4.1.2.5   Mass Spectrometric Detection – Starting Conditions 
 
A Perkin Elmer API 3000 triple quadrupole mass spectrometer was used in positive ion 
mode  to generate protonated molecular ions [M+H]
+,  using a pneumatically and 
thermally assisted electrospray interface (TurboIonSpray).  The mass spectrometer was 
set up in multiple reaction monitoring mode to detect the protonated pseudo-molecular 
ions at m/z 289.2 (testosterone) and 292.2 (testosterone-D3) via the first quadrupole filter 
(Q1), with collisionally induced fragmentation (using nitrogen) at Q2 (collision energy 
40eV) and monitoring the most abundant product ions via Q3 at m/z 97.1 (testosterone) 
and 97.1 (testosterone-D3).  In order to aid evaporation, to optimise sensitivity of the 
assay, the TurboIonSpray drying gas was set at 400°C.  Chromatographic peak areas 
were obtained for the transitions m/z 289.2→97.1 (testosterone) and m/z 292.2→97.1 
(testosterone-D3).  Linear regression of response (peak area ratio 
testosterone:testosterone-D3) against concentration, employing the reciprocal of 
concentration as weighting, was used to generate the calibration function 99 
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4.1.3  Results and Discussion 
 
4.1.3.1  Analytical Approach 
 
Testosterone-D3 was used as the internal standard to help compensate for any potential 
inter-species variations in recovery, or matrix related modification of ionisation. 
 
In order to compensate for the low levels of testosterone in anticipated sample studies, 
equine (gelding) serum was used as the matrix for the preparation of the calibration 
samples and for the LLOQ QC (50 pg.mL
-1).  A number of samples of female human 
serum were screened and one with a relatively low concentration was selected as the low 
QC.  This serum had additional quantities of testosterone added to it to provide the other 
QC concentrations.  All QC tables include compensation for the endogenous amount of 
testosterone in this serum. 
 
The validation consisted of three different batches run on separate days used for the 
accuracy and precision data and a fourth batch (also run on a separate day) to assess 
matrix related modification of ionisation. 
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4.1.3.2  Accuracy and Precision 
 
The  inter-batch precision of the analytical method was defined as the coefficient of 
variation of the observed concentration for all QC replicates analysed within batches 
designated as being part of the assessment of accuracy and precision, at each 
concentration level.  For this to be acceptable, it was required to be less than, or equal to, 
15% at all levels, other than at the LLOQ, at which precision was required to be less than, 
or equal to, 20%.  The mean inter-batch accuracy was required to be 85 to 115% of the 
nominal concentration at all levels, other than at the LLOQ, at which accuracy could have 
been 80 to 120% of the nominal concentration. 
 
Inter-batch precision ranged between 4.0% and 14.1%.  Inter-batch accuracy ranged 
between 93.6% and 106.2%.  The method was therefore acceptable at all QC levels. 
(Table 4.1.1). 
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Table 4.1.1  Inter-batch precision and accuracy of quality control sample data.  N.B. The QC 2000, 12000 and 25000 have been 
corrected for the endogenous level (i.e. the mean endogenous level has been subtracted from the observed concentration). 
50                       
(pg.mL
-1)
E*                 
(pg.mL
-1)
E* +    2000 
(pg.mL
-1)
E* + 12000 
(pg.mL
-1)
E* + 25000 
(pg.mL
-1)
55.5 111.0 372 - 2080 104.0 13750 110.0 27750 111.0
53.8 107.6 352 - 2110 105.5 13450 107.6 27450 109.8
48.0 96.0 322 - 2110 105.5 13450 107.6 27350 109.4
38.9 77.8 349 - 2110 105.5 13750 110.0 26650 106.6
50.2 100.4 439 - 2210 110.5 13050 104.4 27950 111.8
43.5 87.0 358 - 2200 110.0 13550 108.4 27750 111.0
59.3 118.6 348 - 2050 102.5 10650 85.2 27050 108.2
NR - 325 - 1980 99.0 12550 100.4 26750 107.0
32.8 65.6 360 - 1990 99.5 11850 94.8 27250 109.0
48.2 96.4 304 - 1990 99.5 12450 99.6 25950 103.8
40.7 81.4 313 - 2030 101.5 12450 99.6 26750 107.0
54.2 108.4 319 - 1990 99.5 12150 97.2 26450 105.8
45.7 91.4 349 - 1990 99.5 12250 98.0 27050 108.2
45.3 90.6 301 - 1980 99.0 12150 97.2 26050 104.2
43.8 87.6 320 - 1850 92.5 12150 97.2 24650 98.6
41.8 83.6 356 - 1870 93.5 12050 96.4 25650 102.6
47.1 94.2 267 - 1860 93.0 12050 96.4 24350 97.4
46.8 93.6 261 - 1850 92.5 11950 95.6 25250 101.0
Mean 46.8 334.2 2013.9 12538.9 26561.1
S.D. 6.6 40.6 111.0 815.2 1055.5
Precision (%) 14.1 12.1 5.5 6.5 4.0
Accuracy (%) 93.6 N/A 100.7 104.5 106.2
Inter-batch precision and accuracy of quality control sample data
E* = Endogenous level in selected control female human serum.  The mean has been subtracted from the higher QC levels to enable the calculation of 
accuracy.
Batch 1
Batch 2
Batch 3
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4.1.3.3   Lower Limit of Quantification 
 
The lower limit of quantification (LLOQ), which was defined as the lowest QC at which 
accuracy was within 20% of nominal and precision was no greater than 20% [116], was 
50 pg.mL
-1 (Figure 4.1.2).  This range was suitable for the analysis of both “normal” and 
clinically suppressed levels of testosterone in samples. 
 
 
Figure 4.1.2  MRM chromatogram resulting from the analysis of a quality control 
sample at 50 pg.mL
-1   HPLC system:  PE Sciex API 3000 and PE Series pumps, SIM 
for testosterone and internal standard.  Column Genesis C18 50 x 4.6 mm, 3 µm particles  
Mobile phase methanol - ammonium acetate (pH native; 10 mM), 75:25, v/v, flow rate 1 
mL.min
-1.  The blue trace shows the response for testosterone at the LLOQ, with the red 
trace showing the deuterated internal standard. 
 
0.2  0.4  0.6  0.8  1.0  1.2  1.4  1.6  1.8  2.0  2.2  2.4  2.6  2.8 
Time, min 
0 
500 
1000 
1500 
2000 
2500 
3000 
3500 
4000 
4500 
5000 
Intensity, cps 
 103 
________________________________________________________________________ 
 
 
 
4.1.3.4   Linearity 
 
The range was selected following the preliminary analysis data.  Linearity was 
demonstrated over the range 50 pg.mL
-1 to 25000 pg.mL
-1, using a linear regression of 
peak area ratio (testosterone:internal standard) versus concentration, using the reciprocal 
of concentration as weighting, as this is considered likely to provide the best fit of data 
over the dynamic range investigated [117, 118]. 
 
All coefficients of determination (r
2) of the calibration lines obtained during the 
validation were equal to, or better than, 0.9962. 
 
Linearity data for all calibration lines used in the assessment of inter-batch precision and 
accuracy are shown in Table 4.1.2. 
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Table 4.1.2  Inter-batch precision and accuracy of calibration sample data. 
N.B. All calibration samples are prepared in equine (gelding) serum. 
 
Nominal Concentration (pg.mL
-1) 50 100 500 2000 10000 15000 22500 25000
Batch 1 40.7 101 541 2010 11400 15300 21500 24300
Batch 2 51.0 106 492 1850 10000 15000 22900 24800
Batch 3 52.5 98.1 524 1870 9580 15000 24000 23900
Mean (pg.mL
-1) 48.1 102 519 1910 10300 15100 22800 24300
Standard Deviation (n-1) 6.42 4.00 24.9 87.2 953 173 1250 451
Precision (%) 13.3 3.9 4.8 4.6 9.3 1.1 5.5 1.9
Accuracy (%) 96.2 102.0 103.8 95.5 103.0 100.7 101.3 97.2
Batch 1
Batch 2
Batch 3
0.9998
0.000089
0.000098
0.00174
0.00198
0.000100 0.00263
Curve parameters
Inter-batch precision and accuracy of calibration sample data
0.9976
Gradient (m) Intercept (c) 
Coefficient of 
Determination 
0.9962
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4.1.3.5   Stability 
 
Freeze / Thaw Stability 
Stability investigations were performed on serum that had undergone an additional three 
freeze / thaw cycles (above the single cycle that all quality control samples were given 
following preparation).  Comparison of the freeze / thaw investigation samples with 
samples which had only undergone a single cycle (run in the same analytical batch) 
showed changes from baseline of ≤8.8%.  Each freeze/thaw cycle consisted of a thaw of 
not less than 2 hours, where the plasma was visibly confirmed to have been thawed and a 
freeze of not less than 24 hours at -20°C. 
 
These results showed that testosterone is stable in serum, when exposed to at least four 
freeze / thaw cycles. 
 
Freeze/thaw stability data are shown in Table 4.1.3. 
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Table 4.1.3  Freeze/thaw stability of testosterone.  Baseline QC samples underwent a single freeze/thaw cycle, with the stability 
QCs being subjected to an additional 3 freeze/thaw cycles (i.e. a total of 4 cycles).  All samples were extracted and run in the same 
analytical batch. 107 
 
 
Observed concentration            
(pg.mL
-1)
Mean (pg.mL
-1)  
(CV%)
Observed concentration 
(pg.mL
-1)
Mean (pg.mL
-1)  
(CV%)
372 329
352 330
322 365 307 333 -8.8
349 (10.8) 357 (5.5)
439 325
358 351
2430 2520
2460 2540
2460 2490 2480 2530 1.6
2460 (2.2) 2590 (1.7)
2560 2540
2550 2480
14100 14400
13800 14100
13800 13900 14000 14000 0.7
14100 (1.9) 14000 (1.6)
13400 13700
13900 14000
HiQC
Baseline QC samples QC samples subjected to 3 additional 
freeze/thaw cycles prior to extraction Difference 
from baseline 
(%)
Quality control 
level
LoQC
MeQC
 107 
________________________________________________________________________ 
 
Room Temperature In-Matrix Stability 
The stability of testosterone in serum, stored at room temperature for 24 h before being 
frozen, was assessed.  Comparison of the concentrations of testosterone  observed in 
investigational samples stored at room temperature with those observed in samples which 
were frozen immediately after preparation (run in the same analytical batch) showed 
changes from baseline of ≤6.7%.  These results showed that testosterone is stable in 
serum for at least 24 h when stored at room temperature. 
 
Room temperature in-matrix stability data are shown in Table 4.1.4. 
 108 
 
 
Table 4.1.4  Room temperature stability of testosterone.  Baseline QC samples were frozen immediately following preparation, 
with the stability QCs being stored at room temperature for 24 hours prior to storage.  All samples were extracted and analysed in the 
same analytical batch. 
Observed concentration 
(pg.mL
-1)
Mean (pg.mL
-1)  
(CV%)
Observed concentration 
(pg.mL
-1)
Mean (pg.mL
-1)  
(CV%)
348 321
325 420
360 328 322 350 6.7
304 (6.6) 359 (11.2)
313 319
319 358
2400 2370
2330 2510
2340 2360 2290 2390 1.3
2340 (1.2) 2270 (4.1)
2380 2430
2340 2480
11000 12700
12900 12300
12200 12400 12400 12600 1.6
12800 (5.8) 12400 (2.3)
12800 13100
12500 12600
Difference 
from baseline 
(%)
LoQC
MeQC
HiQC
Quality control 
level
Baseline QC samples QC samples subjected to approximately 
24 hours storage at room temperature
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Stability of Prepared Samples 
Samples that had undergone the sample preparation procedure were left at room 
temperature for 1 week before being subjected to the LC-MS/MS analysis.  Comparison 
of stored, prepared samples with freshly prepared samples (run in the same analytical run, 
with a freshly prepared calibration line) showed changes from baseline of ≤0.9%.  
Prepared samples were therefore stable when stored at room temperature, for at least one 
week. 
 
Stability data for samples stored at room temperature for 1 week before analysis is shown 
in Table 4.1.5. 110 
 
 
Table 4.1.5  Extract stability of testosterone.  Baseline QC samples were injected immediately following preparation.  Stability QC 
sample extracts were stored at room temperature for 7 days prior to injection (in the same analytical batch). 
Observed concentration 
(pg.mL
-1)
Mean (pg.mL
-1)  
(CV%)
Observed concentration 
(pg.mL
-1)
Mean (pg.mL
-1)  
(CV%)
349 342
301 363
320 309 307 308 -0.3
356 (13.0) 240 (13.8)
267 302
261 295
2340 2390
2330 2330
2200 2250 2230 2270 0.9
2220 (2.9) 2290 (3.7)
2210 2210
2200 2160
12600 12800
12500 13100
12500 12500 12400 12600 0.8
12400 (0.8) 12300 (2.4)
12400 12400
12300 12700
Difference 
from baseline 
(%)
LoQC
MeQC
HiQC
Quality control 
level
Baseline QC samples QC sample extracts subjected to 7 days' 
room temperature storage
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4.1.3.6   Specificity 
 
The limitations imposed by investigating specificity with an endogenous analyte, 
principally involving the problems associated with getting a sample clear of the analyte, 
were considered when designing the specificity investigation.  Taking these into account 
equine (gelding) serum blanks that had been prepared in the same manner as quality 
control samples were investigated for the presence of interfering peaks in the MRM 
chromatograms at retention times corresponding to testosterone or testosterone-D3.  No 
interfering peaks were detected. 
 
Potential interference from other endogenous and commonly administered steroids was 
considered based on structural characteristics.  The compounds, with their molecular 
masses for mass spectrometric determination in brackets, considered were aldosterone 
(360), 5β-androstan-3α,17β-diol (292), androstenedione (286), 5α-androstan-3β,17β-diol 
(292),  5α-androstan-3,17-dione  (288*), 5-androsten-3β,17β-diol  (290), androsterone 
(290), corticosterone  (346), cortisol  (362), cortisone  (360), danazol (337), 
11-deoxycortisol  (346), dexamethasone  (392), dehydroepiandrosterone  (288*), 
dehydroepiandrosterone sulphate (288*), 5α-dihydrotestosterone (290), estradiol (272), 
estrone  (270), ethisterone  (312), fluoxymesterone  (336), 11-ketotestosterone  (304), 
methyltestosterone  (302), norethindrone  (298), norethynodrel  (298), prednisone  (358), 
progesterone  (314), spironolactone  (416)  and triamcinolone  (394).  These were 
considered as they are the steroids specified in standard immuno-assay diagnostic tests 
for testosterone  [119, 120, 121].  Where the molecular mass is at least 1  mass unit 112 
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different to testosterone (288) or testosterone-D3 (291) there is no significant likelihood 
of producing any parent ion that would interfere with these analytes.  Where the steroid’s 
molecular mass is within 1 mass unit (those indicated by *), the structures indicate that 
they would not produce the product ion (containing the double bond at carbon 4) with a 
significant response. 
 
These investigations indicated that the method was specific enough for the determination 
of testosterone in human serum. 
 
4.1.3.7   Matrix-related modification of ionisation 
 
 A calibration line was prepared in each of six different human (female) sera.  They were 
analysed according to the method, and their regression characteristics were calculated. 
The slopes of the lines were compared with that from a calibration line prepared in 
control equine (gelding) serum.  Differences of less than or equal to ±15% were 
considered to be acceptable, within the predefined acceptance criteria. 
 
All of the individual calibration lines met this acceptance criterion (a maximum of 5.9% 
difference was observed). 
 
Matrix-related modification of ionisation data are shown in Table 4.1.6. 113 
 
 
Table 4.1.6  Matrix-related modification of ionisation.  A comparison of the regression lines produced by preparing calibration 
standards in a range of female human urines with a line compared in equine (gelding) serum. 
Eq/S/01/002 -
Hu/S/01/001 335
Hu/S/01/002 471
Hu/S/01/003 199
Hu/S/01/004 387
Hu/S/01/005 202
Hu/S/01/006 248 4.0
Matrix
3.0
0.0206 0.9994 5.9
4.0
0.0199 1.0000 4.0
-
0.0335 0.9986 4.0
Curve parameters
Difference in slope 
from equine line (%)
Coefficient of 
Determination (r
2)
Intercept (c) 
0.000102
0.000100 0.0248 0.9992
0.000100
0.000099 0.0382 0.9994
0.000100 0.0470 0.9996
0.0018 0.9988
Gradient (m)
Endogenous 
level (pg.mL
-1)
0.000096
0.000100
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4.1.4  Conclusion 
 
The LC-MS/MS method developed for the rapid and simple determination of testosterone 
in human serum not only complied with international standards [122]
 on all aspects of its 
validation but also delivered the anticipated advantages over existing methodology [123] 
with respect to sensitivity for measuring clinically suppressed levels of testosterone. This 
would be useful in dealing with studies of appropriate size to give convincing statistical 
power and, indeed, the method has already been used in the analysis of samples from a 
large clinical study, in which testosterone  levels have been measured in patients 
undergoing treatment for prostate cancer.  As a result of this major clinical study, the 
method has been shown to be suitable for the routine monitoring of clinically suppressed 
serum testosterone levels. 
 
The results of this investigation provide good evidence to suggest that adoption of this 
approach to overcoming the problem of developing a robust method for the analysis of an 
endogenous analyte was both suitable in this case and may be applicable for more 
widespread use, where the target analyte can be isolated by use of a surrogate matrix.  
Due to difficulties in obtaining suitable surrogate matrices possessing significant 
similarities to the test matrix, but with the target analyte either absent, or present in 
insignificant levels, this is likely to remain a relatively rare, though extremely useful 
when applicable, solution to the problem of analysis of endogenous analytes.  115 
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4.2  Development and Validation of an Analytical Method for the Determination 
of Indolyl-3-AcryloylGlycine in Human Urine using LC-MS/MS 
 
4.2.1  Introduction 
 
Indolyl-3-acryloylglycine (IAG) (Fig. 4.2.1) has been implicated in learning disorders 
such as core autism, atypical autism and Asperger’s Syndrome (a range of developmental 
disorders  in that sufferers display  abnormal and/or impaired development  in  social 
interaction, communication, and restrictive, stereotyped, repetitive behaviour).  Atypical 
autism is diagnosed most readily in profoundly retarded individuals whose very low level 
of functioning provides little scope for exhibition of the specific deviant behaviours 
required for the diagnosis of autism.  Persons with Asperger’s Syndrome show marked 
deficiencies in social skills and have difficulties with changes in routine or environment. 
They frequently have obsessive routines and are obsessive about a particular subject of 
interest.  They have a great deal of difficulty in interpreting body language. 
 
 There has been significant research on trying to establish biomarkers for these conditions 
[124] in order to both investigate the disorders at an early stage and to try to determine 
the metabolic causes of the disorders.  It has been postulated that high urine levels of 
IAG, resulting from abnormal tryptophan metabolism, indicates an increase in the 
permeability of the gut wall and blood brain barrier to exogenous peptides [125, 126].  
According to this hypothesis the increase in these exogenous peptides may result in 116 
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effects which are opioid-like in nature, leading to learning difficulties.  Presence of an 
elevated level of IAG in the urine has been reported in autistic children [127] and it has 
been postulated that IAG may be diagnostic for these conditions [128]. The aim of this 
study therefore was to develop an analytical method suitable for monitoring levels of IAG 
in urine in the types of large clinical studies that would be needed to establish once and 
for all whether IAG is a biomarker for autism spectrum disorders.  Such a method would 
need to be not only specific to IAG but also be sufficiently  sensitive to be able to 
quantify IAG in both anticipated  elevated levels in samples from autistic children and 
possible lower levels in samples from non-autistic “controls”. 
 
N
N
O
OH
O
H
H
H
H
H
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Figure 4.2.1  Structure of indolyl-3-acryloylglycine 
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4.2.2  Experimental 
4.2.2.1 Materials 
 
A research group based at the Child and Adolescent Mental Health Unit, University of 
York, which included representatives of the University of York Chemistry and 
Biochemistry departments was formed for a range of investigations into the biochemical 
pathways of autism spectrum disorders.   IAG was synthesised by Professor D.K. Smith 
of  the University of York,  using  a method which involved esterification of 
indole-3-acrylic acid with glycine methyl ester using dicyclohexylcarbodiimide and 
hydroxybenzotriazole in dichloromethane [129]. 
 
In addition, a dideuterated analogue of IAG (d2-IAG) was synthesised using the same 
route from glycine-2,2-d2 methyl ester, which was synthesised from glycine-2,2-d2 [116]. 
 
4.2.2.2 Instrumentation 
 
The system used for this work consisted of a PE Series 200 Micro-pump (Perkin Elmer, 
Thornhill, Ontario, Canada), an on-line DGU-14A degasser (Shimadzu, Kyoto, Japan), 
and an HTC PAL autosampler (CTC Analytics AG, Zwingen, Switzerland) connected to 
a Perkin Elmer API 3000 triple quadrupole mass spectrometer (Perkin Elmer, Thornhill, 
Ontario, Canada).  Chromatographic system control, data acquisition and analysis were 
performed by means of Analyst software version 1.2 (Applied Biosystems – MDS Sciex, 
UK). 118 
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4.2.2.3 Chromatographic Conditions 
 
 
Indolyl-3-acryloylglycine and d2-indolyl-3-acryloylglycine were separated from matrix 
components using a Luna phenyl-hexyl analytical column (50 mm x 4.6 mm, 3 µm 
particle, Phenomenex, UK).  The mobile phase was a mixture of 30% acetonitrile and 
70% water containing 0.1% formic acid and was delivered at a flow rate of 1 mL.min
-1.  
The retention time for both IAG and d2-IAG was 1.6 min. 
 
4.2.2.4 Sample Preparation 
 
 
An aliquot of 20 µL of urine was taken from a thoroughly mixed sample tube and added 
to a polypropylene tube.  Internal standard (d2-IAG, 20 µL of a 10 µg.mL
-1 solution) was 
added to each tube.  1 mL of mobile phase (acetonitrile - 0.1% v/v formic acid, 30:70, v/v) 
was added to each tube.  The tubes were then vortex mixed and an aliquot transferred to a 
96-well polypropylene injection plate ready for LC-MS-MS analysis.  All sample 
preparation was performed under monochromatic (sodium) lighting  to prevent 
isomerisation between the trans and cis forms of IAG. 
 
4.2.2.5 Tandem Mass Spectrometric Detection 
 
A Sciex API 3000 triple quadrupole mass spectrometer was used with a TurboIonSpray 
(temperature and pneumatically assisted electrospray) interface used in the negative ion 119 
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mode to generate deprotonated molecular ions [M-H]
+.  The mass spectrometer was set 
up in multiple reaction monitoring mode to detect the deprotonated pseudo-molecular 
ions at m/z 243.2 (IAG) and 245.2 (d2-IAG) via the first quadrupole filter (Q1), with 
collisionally induced fragmentation (using nitrogen) at Q2 (collision energy 26eV) and 
monitoring the product ions via Q3 at m/z 142.0 (IAG) and 142.0 (d2-IAG).  In order to 
aid ion evaporation, to optimise sensitivity of the assay, the TurboIonSpray was set at 
400°C.  Chromatographic peak areas were obtained for the transitions m/z 243.2→142.0 
(IAG) and m/z 245.2→142.0 (d2-IAG).  Linear regression of response (peak area ratio 
IAG:d2-IAG) against concentration, employing the reciprocal of concentration as 
weighting, was used to generate the calibration function. 
 
4.2.3  Results and Discussion 
 
4.2.3.1 Analytical Approach 
 
A routine assay for indolyl-3-acryloylglycine in urine had been reported [129], which 
employed HPLC with UV detection at 326 nm. However, given the power of modern 
methods in LC-MS/MS it was felt that there was considerable scope for improving upon 
this method for bioanalysis.  For example, although indolyl-3-acryloylglycine provides a 
strong signal at 326 nm there are many potential interfering species which may not be 
discriminated against with this relatively non-specific technique. LC-MS/MS is a highly 
specific technique, with extremely high sensitivity, which would be expected to provide a 
robust assay, which would dramatically reduce the likelihood of false readings being 120 
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reported when analysing patient samples.    Because of this it would more likely be 
possible to fulfil the objective of developing and validating a method to match and 
hopefully exceed rigorous, internationally recognised, standards [74]. 
 
Perhaps as importantly, one of the main advantages of using LC-MS/MS is the ability to 
utilise low run times, with the associated high throughput, which may be required for 
studies with large numbers of samples, which are required to provide appropriate 
statistical power.  A further advantage of this methodology is  the availability of 
dideuterated IAG to be used as the internal standard.  Using a stable, isotopically labelled 
analogue of the primary analyte as the internal standard would provide a huge degree of 
confidence that most of the potential causes of inaccuracy (such as extraction, adsorption 
and particularly modification of ionisation issues) would be eliminated. 
 
Sample preparation was kept to a minimum, as the instrument response for the analytes 
was extremely high.  Therefore there was no requirement to remove interfering species 
and simple dilution was used. 
 
Preliminary analyses indicated that, as had been experienced by Mills et al [129], IAG 
was found in all human urine samples (autistic and non-autistic).  The preliminary 
analyses involved over 20 different urines, from males and females, of a wide range of 
adult ages and a number of ethnic backgrounds.  A range of 1.26 to 13.7 µg.mL
-1 was 
found in these non-autistic, adult samples.  It was therefore necessary to employ 
non-matrix calibration standards, having first established that urine components did not 121 
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significantly affect the response of IAG  (Section 4.2.4.7).  In addition, the use of a 
dideuterated internal standard was adopted in order to assist in compensating for any 
variability in individual matrix sources, by eliminating any matrix-related modification of 
ionisation. 
 
The validation exercise consisted of three different batches run on separate days used to 
assess the accuracy and precision of the method, a fourth batch (also run on a separate 
day) to assess matrix-related modification of ionisation and a fifth batch to assess the 
stability of IAG in urines at various pH values.  This assessment of stability at various pH 
values was in excess of the requirements of the stated validation standards [116], but was 
included to ensure the robustness of the method. 
 
4.2.3.2 Accuracy and Precision 
 
The inter-batch precision of the analytical method was defined as the coefficient of 
variation of the observed concentration for all QC replicates analysed within batches 
designated as being part of the assessment of accuracy and precision, at each 
concentration level.  For this to be acceptable, it was required to be less than, or equal to, 
15% at all levels, other than at the LLOQ, at which precision was required to be less than, 
or equal to, 20%.  The mean inter-batch accuracy was required to be 85 to 115% of the 
nominal concentration at all levels, other than at the LLOQ, at which accuracy could have 
been 80 to 120% of the nominal concentration. 
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Inter-batch precision ranged between 2.8% and 14.1%.  Inter-batch accuracy ranged 
between 89.9% and 101.4%.  The method was therefore acceptable at all QC 
levels (Table 4.2.1). 
 
Table 4.2.1  Inter-assay accuracy and precision data  for IAG in human urine.  
+LoQC is blank urine (containing an endogenous level of 2.36 µg.mL
-1).  QCs 30 and 70 
are prepared from the same urine with the nominal concentration added. 
Nominal 
concentration 
(µg.mL
-1)
Mean observed 
concentration 
(µg.mL
-1)
Precision 
(CV %)
Mean 
accuracy (%)
n
0.5 0.507 14.1 101.4 18
LoQC
+ 2.36 9.0 n/a 18
30
+ 29.1 10.9 89.9 18
70
+ 70.8 7.5 97.8 18
100 101 2.8 101 18
+ LoQC is blank urine (containing an endogenous level of 2.36 µg.mL
-1).         
QC 30 and QC 70 are prepared from the same urine with the nominal 
concentration added.  
 
4.2.3.3 Lower Limit of Quantification 
 
The lower limit of quantification (LLOQ), which was defined as the lowest QC at which 
accuracy was within 20% of nominal and precision was no greater than 20% [74], was 
0.5 µg.mL
-1 (Figure 4.2.2).  This range comfortably encompassed the anticipated range of 
IAG in samples, which was determined based on a screen of samples from a range of 
subjects.  (Sensitivity of the analytical technique was such that a far lower limit of 123 
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quantification could have been selected if the expected urine concentrations had been at a 
lower range.) 
 
      
 
Figure 4.2.2  MRM chromatogram resulting from the analysis of a standard at 
0.5 µg.mL
-1   HPLC system:  PE Sciex API III and PE Series 200 pumps, SIM for IAG 
and internal standard.  Column Luna phenyl-hexyl 50 x 4.6 mm, 3 µm.  Mobile phase 
acetonitrile - water - formic acid (30:70:0.1, v/v/v), flow rate 1.0 mL.min
-1.  The trace 
shows the response for IAG at the LLOQ, with the red trace showing the deuterated 
internal standard. 
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4.2.3.4 Linearity 
 
The range was selected following the preliminary analysis data.  Linearity was 
demonstrated over the range 0.5 µg.mL
-1 to 100 µg.mL
-1, using a linear regression of 
peak area ratio (IAG:internal standard) versus concentration, using the reciprocal of 
concentration as weighting as this is considered likely to provide the best fit of data over 
the dynamic range investigated [117]. 
 
Linearity data are shown in Table 4.2.2. 
 
All coefficients of determination (r
2) of the calibration lines obtained during the 
validation were equal to, or better than, 0.9968. 
 
Calibration curve data are shown in Table 4.2.3 and Figure 4.2.4. 125 
 
Table 4.2.2  Precision and accuracy of calibration standard data for IAG in human urine. 
0.500 1.00 2.00 5.00 20.0 50.0 80.0 100
HuUV01 0.488 0.999 2.08 4.85 20.0 50.6 82.3 97.2
HuUV02 0.505 0.990 2.02 4.71 21.1 50.7 78.7 99.8
HuUV03 0.462 0.960 2.07 5.18 19.9 55.2 79.0 95.7
HuUV04 0.529 - 1.84 4.91 21 48.9 83.6 96.8
Mean (µg.mL
-1) 0.496 0.983 2.00 4.91 20.5 51.4 80.9 97.4
Standard Deviation (n-1) 0.0282 0.0204 0.111 0.197 0.638 2.70 2.43 1.74
Precision (%) 5.7 2.1 5.6 4.0 3.1 5.3 3.0 1.8
Accuracy (%) 99.2 98.3 100.0 98.2 102.5 102.8 101.1 97.4
Calibration level (µg.mL
-1)
Back-calculated concentrations (µg.mL
-1)
Batch126 
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Table 4.2.3  Curve parameters of calibration standard regression lines for IAG in 
human urine. 
HuUV01
HuUV02
HuUV03
HuUV04
HuUV05i
0.9996
0.9968
Curve parameters
Batch
0.0885 0.007260 0.9998
Gradient (m) Intercept (c) 
Coefficient of 
Determination 
0.9994
0.0820
0.9986
0.0849
0.0817
0.007700
0.006100
0.0821
0.000176
0.012200
 
 
4.2.3.5 Stability 
 
Freeze / Thaw Stability 
Stability investigations were performed on urine that had undergone an additional three 
freeze / thaw cycles (above the single cycle that all quality control samples were given).  
Comparison of the freeze / thaw investigation samples with samples which had only 
undergone a single cycle (run in the same analytical batch) showed changes from baseline 
of ≤7.7%.  These results showed that IAG is stable in urine, when exposed to at least four 
freeze / thaw cycles. 
 
Freeze/thaw stability data are shown in Table 4.2.4. 127 
 
 
Table 4.2.4  Stability of IAG in human urine following four freeze/thaw cycles. 
Observed concentration            
(µg.mL
-1)
Mean (µg.mL
-1)  
(CV%)
Observed concentration 
(µg.mL
-1)
Mean (µg.mL
-1)  
(CV%)
2.00 2.47
1.92 2.30
2.30 2.22 2.54 2.39 7.7
2.03 (12.6) 2.09 (7.0)
2.62 2.45
2.44 2.48
34.6 30.8
35.7 -
31.8 33.6 33.6 31.9 -5.1
30.1 (6.9) 34.5 (9.9)
36.1 26.9
33.5 33.9
79.6 56.8
80.2 72.8
64.5 73.5 69.0 68.7 -6.5
71.3 (7.9) 76.3 (9.6)
73.5 69.7
72.0 67.6
HiQC
Baseline QC samples QC samples subjected to 3 additional 
freeze/thaw cycles prior to extraction Difference 
from baseline 
(%)
Quality control 
level
LoQC
MeQC
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In addition, investigations were carried out into the stability of IAG in urines at pH 5, 6 
and 7 following three additional freeze / thaw cycles.  All differences from samples that 
had only undergone a single freeze / thaw cycle were ≤9.7%.  These results showed that 
there was no significant change in the urinary IAG concentrations following these 
additional freeze / thaw cycles. 
 
Room Temperature In-Matrix Stability 
The stability of IAG in urine, stored at room temperature for 24 h before being frozen, 
was assessed.  Comparison of the concentrations of IAG observed in investigational 
samples stored at room temperature with those observed in samples which were frozen 
immediately after preparation (run in the same analytical batch) showed changes from 
baseline of ≤3.8%.  These results showed that IAG is stable in urine for at least 24 h 
when stored at room temperature. 
 
Room temperature in-matrix stability data are shown in Table 4.2.5. 129 
 
 
Table 4.2.5  Stability of IAG in human urine following storage at room temperature for 24 hours. 
Observed concentration            
(µg.mL
-1)
Mean (µg.mL
-1)  
(CV%)
Observed concentration 
(µg.mL
-1)
Mean (µg.mL
-1)  
(CV%)
2.15 2.18
2.46 2.30
2.26 2.35 2.28 2.26 -3.8
2.46 (5.8) 2.34 (4.8)
2.28 2.37
2.47 2.08
31.7 28.6
28.8 27.4
31.2 30.1 27.9 29.6 -1.7
29.6 (6.8) 35.6 (10.2)
26.9 28.8
32.3 29.1
63.6 68.1
74.8 71.2
75.1 71.3 79.5 73.9 3.6
77.1 (8.6) 73.7 (6.1)
73.8 79.0
63.3 71.8
Difference 
from baseline 
(%)
LoQC
MeQC
HiQC
Quality control 
level
Baseline QC samples QC samples subjected to 24 hours 
storage at room temperature
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In addition, stability investigations were carried out in urines at pH 5, 6 and 7 which had 
been stored at room temperature for 24 h before freezing.  All differences from samples 
that had been frozen immediately upon preparation were ≤6.1%.  These results showed 
that there was no significant change in the urinary IAG concentrations following this 
additional room temperature storage. 
 
The above investigations indicated that the pH of the urine (over the normal range 
expected in man) is not a significant factor in the stability of IAG. 
 
Stability of Prepared Samples 
Samples that had undergone the sample preparation procedure were left at room 
temperature for 1 week before being subjected to the LC-MS/MS analysis.  Comparison 
of stored, prepared samples with freshly prepared samples (run in the same analytical run, 
with a freshly prepared calibration line) showed changes from baseline of ≤10.8%.  
Prepared samples were therefore stable when stored at room temperature, for at least one 
week. 
 
Extract (prepared sample) stability data are shown in Table 4.2.6. 131 
 
 
Table 4.2.6  Stability of IAG in human urine extracts following storage at room temperature for 1 week. 
Observed concentration            
(µg.mL
-1)
Mean (µg.mL
-1)  
(CV%)
Observed concentration 
(µg.mL
-1)
Mean (µg.mL
-1)  
(CV%)
2.00 2.41
1.92 2.65
2.30 2.22 2.50 2.46 10.8
2.03 (12.6) 2.39 (4.3)
2.62 2.36
2.44 2.47
34.6 29.2
35.7 31.9
31.8 33.6 35.3 30.3 -9.8
30.1 (6.9) 33.4 (13.3)
36.1 27.6
33.5 24.3
79.6 73.4
80.2 74.1
64.5 73.5 70.1 73.8 0.4
71.3 (7.9) 74.5 (3.2)
73.5 77.4
72.0 73.1
Difference 
from baseline 
(%)
LoQC
MeQC
HiQC
Quality control 
level
Baseline QC samples QC sample extracts subjected to room 
temperature storage for 1 week
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4.2.3.6 Specificity 
 
The limitations imposed by investigating specificity with an endogenous analyte, 
principally involving the problems associated with getting a sample clear of the analyte, 
were considered when designing the specificity investigation.  Taking these into account 
reagent blanks that had been prepared in the same manner as quality control samples 
were investigated for the presence of interfering peaks in the MRM chromatograms at 
retention times corresponding to IAG or d2-IAG.  No interfering peaks were detected.  
This, combined with the investigations comparing a variety of matrices with samples 
prepared in solvent, which showed no differences in response, indicate that the method 
provided the required specificity for the determination of IAG in human urine. 133 
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Figure 4.2.3  MRM chromatogram resulting from the analysis of a reagent blank.
   
HPLC system:  PE Sciex API III and PE Series 200 pumps, SIM for IAG and internal 
standard.  Column Luna phenyl-hexyl 50 x 4.6 mm, 3 µm.  Mobile phase acetonitrile - 
water - formic acid (30:70:0.1, v/v/v), flow rate 1.0 mL.min
-1.  The blue trace shows the 
response for IAG at the LLOQ, with the red trace showing the deuterated internal 
standard. 
 
4.2.3.7 Matrix-Related Modification of Ionisation 
 
A calibration line was prepared in each of six individual human urines, with varying 
endogenous levels of IAG (the endogenous levels of IAG found in the six different urines 
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ranged from 2.98 to 14.7 µg.mL
-1), and the slope compared to that of a calibration line 
prepared in methanol – water (50:50, v/v).  The slopes of all seven lines were extremely 
similar (the maximum difference in slope between the pure standard (calibration) line and 
the human urine lines was 4.1%), therefore providing evidence that there was no 
matrix-related modification of ionisation for IAG under  the conditions being used 
(Figure 4.2.4, Table 4.2.7).  This experiment also confirmed that the decision to use 
non-matrix calibration standards would provide calibration standards suitable for the 
determination of the levels of IAG in human urine samples. 
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Figure 4.2.4  Calibration lines for matrix-related modification of ionisation test, 
illustrating similarity in slope at various endogenous levels.   The similarity in the 
slopes shows that the response of IAG is linear with the same relationship in all cases.  It 
is therefore acceptable to adopt the methodology of using non-matrix calibration 
standards. 135 
 
 
Table 4.2.7  Matrix-related modification of ionisation data:  comparison of calibration lines from different individual urines 
containing various endogenous levels of IAG. 
Matrix
Endogenous 
level (µg.mL
-1)
Difference from 
baseline (%)
Methanol-water, 1:1, v/v n/a -
Urine 1 2.98 +1.0
Urine 2 13.7 +1.8
Urine 3 7.90 +2.3
Urine 4 4.57 +1.4
Urine 5 14.7 -0.5
Urine 6 10.7 +4.1
Curve parameters
Gradient (m) Intercept (c)
Coefficient of 
Determination (r
2)
0.0885 0.00726 0.9998
0.0894 0.271 0.9994
0.0901 1.22 0.9976
0.0905 0.706 0.9994
0.0921 0.951 0.9992
0.0897 0.412 0.9974
0.0881 1.31 0.9982
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4.2.4  Conclusions 
 
The LC-MS/MS method developed for the rapid and simple determination of IAG in 
human urine not only complied with international standards [74]
 on all aspects of its 
validation but also delivered the anticipated advantages over existing methodology [129] 
with respect to potential for high throughput, and freedom from potential interferences. 
This would be useful in dealing with studies of appropriate size to give convincing 
statistical power and, indeed, the method has already been used in the analysis of samples 
from a large clinical study, in which IAG levels have been compared between autistic 
children, parents and healthy siblings of autistic children, non-autistic learning disorder 
children and age/sex matched children from mainstream schools [130].  The method has 
been shown to be suitable for the routine monitoring of urinary IAG levels, if required.  
In principle a similar approach, i.e. using LC-MS/MS with a stable-isotopically-labelled 
internal standard and non-matrix calibration standards, could be used for biomarkers of 
other conditions. 
 
While not the concern of this research programme this method has been used to indicate 
that the original premise, with regards to the relevance of IAG (at least on its own) was 
not supported.  
 
Both approaches to the development of methods for the analysis of endogenous 
compounds  described in this chapter have shown to be suitable  for their respective 
analytes.  Although most current research into endogenous analytes utilises immunoassay 137 
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methods, some work has been performed using LC-MS [131, 132].  These illustrate that 
the most important factor in choice of methodology is in the robustness of the resulting 
assay, which in the cases reported here was well within the accepted guidelines for the 
required analyses. 
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Chapter 5 
 
 
Promotion of Ionisation:  The Impact of Surfactants on the Ionisation 
Process 
 
 
 
5.1  Introduction 
 
A method for the determination of deltamethrin in bovine and ovine tissues had been 
developed and validated  to comply with recognised regulatory requirements for the 
monitoring of residue levels of agricultural chemicals in animal tissues [133].  During the 
validation process nominal recovery values in excess of 100% had been observed in liver 
tissues for both species (when the actual recoveries in muscle, kidney and skin/fat had 
been in the region of 70% - as confirmed by absolute recovery determinations undertaken 
as part of the validation).  Recoveries of over 100% can be the result of methodological 
errors or as a result of promotion of ionisation.  As the phenomenon of promotion of 
ionisation is so rarely observed this was considered sufficiently unusual to warrant further 
investigation.139 
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It had been postulated by the author that the reason for this phenomenon was that the high 
concentrations of surfactants that are present in the liver  [134]  affect the ionisation 
process, by affecting the properties of the solvent, interferents and/or analyte in solution, 
thereby allowing the promotion of ionisation relative to that for samples extracted from 
other tissues.  The mechanism for this may have been that the purpose of the main group 
of liver surfactants – the bile salts – is to emulsify fats and oils into smaller droplets, 
which can then be broken down enzymatically.  The presence of these fats and oils may 
have been affecting the ionisation process, causing ion suppression in the absence of 
these surfactants. 
 
Almost all examples of matrix-related modification of ionisation in the current literature 
refer to suppression of the analyte signal caused by co-eluting or late eluting interferents 
[64,  135]; therefore this situation whereby matrix components  might have been 
responsible for promotion of ionisation , if occurring would be extremely unusual.   The 
first aim of this programme of investigations was to confirm that this method included 
promotion of ionisation.  Once confirmed the aim was to establish the reason for the 
phenomenon.  Finally, further investigation of this phenomenon was proposed to 
determine whether knowledge of the mechanism could be utilised as a generic 
mechanism for the promotion of ionisation of multiple analytes. 
 
It was therefore sought to determine whether this premise had any validity.  In order to 
fulfil this general aim a series of controlled experiments were performed.  
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5.2  Experimental 
5.2.1  Materials 
 
Deltamethrin was supplied by Sigma-Aldrich (Poole, Dorset, UK).  Analytical grade 
acetonitrile, methanol and n-hexane were supplied by BDH Merck (Poole, Dorset, UK).  
Analytical grade ammonium acetate and anhydrous sodium sulphate were supplied by 
Fisher  Scientific UK (Loughborough, Leicestershire, UK).  A column packed with 
base-deactivated silica material, with phenyl side chains (Hypersil BDS phenyl, 50 x 4.6 
mm, 5 µm) was supplied by ThermoHypersil (Runcorn, Cheshire, UK).  Isolute C2 
96-well extraction blocks were supplied by Argonaut (Hengoed, Pontypridd, UK). 
 
Sodium 1-dodecanesulphonate, benzyldimethyl tetradecylammonium chloride, 
polyoxyethylene 6 lauryl ether and 3-(decyldimethylammonio) propanesulphonate inner 
salt (Zwittergent 3-10) were supplied by Sigma-Aldrich (Poole, Dorset, UK). 
 
5.2.2  Instrumentation 
 
The system used for this work consisted of a PE Series 200 Micro-Pump (Perkin-Elmer, 
Thornhill, Ontario, Canada), an on-line DGU-14A degasser (Shimadzu, Kyoto,  Japan), 
and an HTC PAL autosampler (CTC Analytics AG, Zwingen, Switzerland) connected to 
a Perkin Elmer API 3000 triple quadrupole mass spectrometer.  Chromatographic system 141 
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control, data acquisition and analysis were performed by means of Analyst software 
version 1.2 (Applied Biosystems-MDS Sciex, UK). 
 
5.2.3  Chromatographic conditions 
 
Deltamethrin was separated from matrix components using a Hypersil BDS phenyl 
analytical column.  The mobile phase was methanol –  10 mM aqueous ammonium 
acetate (78:22, v/v) and was delivered at a flow rate of 1 mL/min.  The retention time for 
deltamethrin was 1.9 min. 
 
5.2.4  Sample preparation 
 
Sample preparation was in three stages, i.e. homogenisation, liquid extraction, and then 
solid phase clean-up.  A standard procedure was used for each stage: 
 
5.2.4.1 Sample Homogenisation 
 
Control liver tissues were cut into small pieces (approximately 1 cm
2) and placed into a 
food processor to which dry ice was added.  The food processor was turned on and the 
mixture left to run until the sample had been reduced to a fine powder.  The sample was 
then transferred to a polypropylene storage pot and placed in a freezer at a nominal 142 
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temperature of -20°C, with the lid placed loosely to allow sublimation of the dry ice 
overnight. 
 
5.2.4.2 Liquid Extraction 
 
An aliquot of 1 g of tissue was weighed into a glass tube.  To this was added 1 g of 
anhydrous sodium sulphate and the sample was then vortex mixed.  7 mL of acetonitrile 
was added to each tube, then the samples were macerated using an Ultra-Turrax mixer for 
approximately 30 seconds.  The samples were then centrifuged at 3000 rpm for 5 minutes 
at 20°C.  4.9 mL of the supernatant was transferred into a fresh tube, then 0.5 mL of 
water was added to the tubes and the samples were evaporated in a TurboVap at 55°C 
until about 2-300 µL remained.  200 µL of acetonitrile was added to the tubes, which 
were then vortex mixed for approximately 30 seconds.  Samples were then sonicated for 
5 minutes, then 0.8 mL of de-ionised water was added and the tubes were sonicated for a 
further minute. 
 
5.2.4.3 Solid Phase Extraction 
 
The wells of an Isolute C2, 50 mg 96-well SPE plate were conditioned using 1 mL of 
acetonitrile, then equilibrated with 1 mL of acetonitrile – 10 mM ammonium acetate 
(80:20, v/v) without allowing the packing material to dry.  The prepared samples were 
then added to the plate and the sample tubes were washed with 0.5 mL of water, which 143 
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was then added to each well and mixed with the sample using a Pasteur pipette.  The 
samples were then drawn through the SPE packing material under gentle vacuum.  The 
wells were then washed by the addition of 1 mL of acetonitrile – 10 mM ammonium 
acetate (80:20, v/v) to each well.  This was drawn through the plate under vacuum and 
the wells allowed to dry.  The analyte was eluted into a collection plate using two 
separate aliquots of 0.4 mL of acetonitrile – 10 mM ammonium acetate (20:80, v/v).  
150 µL of ammonium acetate (10 mM) was added to each well and to the wells 
containing calibration standards, which had not undergone the extraction procedure.  The 
collection plate was sealed and vortex mixed prior to submission for mass spectrometric 
analysis. 
 
5.2.5  Tandem Mass Spectrometric Detection 
 
A Sciex API 3000 triple quadrupole mass spectrometer was used with an atmospheric 
pressure chemical ionisation (APCI) interface used in positive ion mode to generate 
protonated molecular ions [M+H]
+.  The mass spectrometer was set up in multiple 
reaction monitoring mode to detect the protonated pseudo-molecular ions at m/z 523.0 via 
the first quadrupole filter, with collisionally induced fragmentation (using nitrogen) at Q2 
(collision energy 25 eV) and monitoring the product ions via Q3 at m/z 281.0.  The APCI 
was set at 350°C.  Chromatographic peak heights were obtained for the transition m/z 
523.0→281.0.  Linear regression of response (peak height) against concentration was 
used to generate the calibration function. 
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5.3  Results and Discussion 
5.3.1  Analytical Approach 
 
The first phase of the study was to confirm that the originally observed promotion of 
ionisation was reproducible.  The original sample preparation methodology as listed 
above had been used to validate an analytical method for the determination of 
deltamethrin to match and exceed rigorous, internationally recognised standards [122].  In 
order to confirm the phenomenon that had been seen during this validation, further liver 
samples,  together with muscle (which had seen no apparent promotion of ionisation 
during the original validation) samples were prepared using this methodology.   
 
Following the premise that surfactants had been responsible for the observed high 
recoveries in the validated method, it was decided to add varying amounts of different 
surfactants to the sample extracts to determine whether any difference in response was 
created. Accordingly a number of extracts of both liver and muscle, spiked to common 
concentrations, were prepared according to the method listed.  To these extracts were 
added quantities of the four main sub-groups of surfactant –  anionic, cationic, 
zwitterionic and non-ionic, to result in concentrations within the samples that were both 
below the critical micelle concentration (cmc) and above the cmc. (The principal 
surfactants expected to be present in liver are the anionic surfactants glycocholic acid and 
taurocholic acid) [136]. 145 
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An example from each of the four main groups of surfactant was selected for 
investigation (i.e. all main types of surfactant rather than just the types expected in liver).  
They were prepared in ammonium acetate (10 mM) in the concentrations listed, then 
added to the final extracts detailed in the sample preparation section of the method in a 
ratio of 1:1, resulting in the final surfactant concentrations as indicated in Table 5.1. 146 
 
 
Table 5.1  Concentrations of surfactants investigated for modification of ionisation. [137, 138, 139] 
(Above CMC) (Below CMC)
Sodium 1-dodecanesulphonate SDS Anionic 7.2 10 1
Benzyldimethyltetradecyl ammonium chloride Zephiramine Cationic 0.37 2.5 0.05
N-decyl,-N, N-dimethyl-3-ammonio-1-propane Zwittergent 3-10 Zwitterionic 25-40 50 0.25
Polyoxyethylene 6 lauryl ether Dodecylhexaglycol Anionic 0.087 0.1 0.005
Sample Concentrations (mM) Surfactant Alternative Name Type of Surfactant Critical Micelle 
Concentration 
(mM)
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As well as the samples to determine the effect of adding surfactant to the sample extracts, 
a number of samples were extracted according to the original sample preparation 
methodology.  In addition, control matrix samples were extracted according to the usual 
sample preparation method and then spiked with deltamethrin to a concentration 
equivalent to 100% recovery through the extraction. 
 
5.3.2  Statistical Treatment of Data 
In the following discussion sections the statistical significance of the relationship between 
sample sets is discussed.  The following formulae [140] were used for these comparisons: 
 
To determine whether the standard deviations of two sample sets are equivalent the F-test 
was used. 
 
Equation 1:        F = s1
2/s2
2 
 
Where s1 and s2 are the standard deviations of the sample sets 1 and 2. 
 
If the standard deviations are not significantly different as determined by equation 1, then 
the standard deviations are pooled using equation 2 and means are compared using the 
t-test detailed in equation 3. 
 
Equation 2:      s
2={(n1-1)s1
2+(n2-1)s2
2}/(n1+n2-2) 
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Equation 3:      t = (x1-x2)/s√(1/n1+1/n2-2) 
 
Where t has n1 + n2 - 2 degrees of freedom. 
 
Where the standard deviations are significantly different, then equation 3 is modified to 
equation 4 and the number of degrees of freedom is calculated by equation 5; 
 
Equation 4:      t = (x1-x2)/√(s1
2/n1+s2
2/n2) 
 
Equation 5:    d.f. = {(s1
2/n1 + s2
2/n2)
2/[(s1
2/n1)
2/(n1+1) + (s2
2/n2)
2/(n2+1)]} – 2 
 
With the result rounded to the nearest whole number. 
 
5.3.3  Promotion of Ionisation in Liver Extracts 
 
Comparison of the quality control samples that underwent the normal extraction 
procedure with samples of extracted control matrix that were spiked to concentrations 
equivalent to 100% recovery was made.  In this way the absolute  recovery of 
deltamethrin from the quality control samples could be assessed. 
 
5.3.3.1 Muscle 
The observed recovery for the muscle samples was 62.1% (Table 5.2), with the spiked 
recovery samples having a mean of 98.1% of the same nominal concentration.  Therefore 149 
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the absolute recovery (mean concentration in extracted samples / mean concentration in 
samples spiked to assume 100% recovery, x 100) was 63.3%.  As there was no significant 
difference between the observed and absolute recoveries, this showed that there was no 
modification of ionisation of deltamethrin in extracts of muscle tissue, following the 
applied methodology. 
 
Table 5.2  Nominal recovery of deltamethrin from muscle. 
Observed 
concentration          
(ng.mL
-1)
Mean 
(CV%)
Observed 
concentration          
(ng.mL
-1)
Mean 
(CV%)
104 65.8
81.1 60.2
99.9 98.1 54.6 62.1
108 10.0 64.2 6.7
92.3 63.2
103 64.7
100
Concentration (ng.mL
-1)
Control matrix extracts spiked 
with test substance and internal 
standard prior to LC-MS/MS
QC sample extracts spiked with 
internal standard prior to           
LC-MS/MS
 
 
5.3.3.2 Liver 
The observed recovery for the liver samples was 77.6% (Table 5.3), with the spiked 
recovery samples having a mean of 118.5% of the same nominal concentration.  
Therefore, from liver the absolute recovery was 64.1%.  These results showed that the 
recovery of deltamethrin from the method was extremely similar between the two tissues 
(63.3% compared with 64.1%).  However the values in the quality control samples 
showed widely differing values (62.1 compared with 77.6).  This significant increase in 
response in the liver tissues was a clear example of promotion of ionisation, which was 150 
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also clear from observation of the observed concentrations found in the spiked recovery 
samples (98.1% for muscle compared with 118.5% for liver).  As it had been sought to 
confirm, the presence of some component of the liver extracts resulted in promotion of 
ionisation of deltamethrin. 
 
Table 5.3  Nominal recovery of deltamethrin from liver. 
Observed 
concentration          
(ng.mL
-1)
Mean 
(CV%)
Observed 
concentration          
(ng.mL
-1)
Mean 
(CV%)
150 94.7
131 91.6
114 118.5 71.9 77.6
104 15.6 72.0 16.8
109 74.5
103 60.7
100
Concentration (ng.mL
-1)
Control matrix extracts spiked 
with test substance and internal 
standard prior to LC-MS/MS
QC sample extracts spiked with 
internal standard prior to           
LC-MS/MS
 
 
5.3.4  Addition of surfactant to tissue extracts 
 
Liver and muscle (which had not seen the enhanced sensitivity found with liver) extracts 
had various amounts of a range of different surfactants added to determine the effect on 
the observed response for deltamethrin. 
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5.3.4.1 Muscle 
 
The observed recovery in samples following the addition of the anionic surfactant sodium 
1-dodecanesulphonate (SDS) at a concentration of 0.5 mM, which is below its cmc of 
7.2 mM, showed a significantly increased response, as measured by a nominal recovery 
of 70.3%, compared with 62.1% for an untreated quality control sample (Table 5.4)).  At 
a concentration of 10 mM, which is above its cmc, the mean nominal recovery was also 
significantly increased to 72.6%. 
 
The observed recovery in samples following the addition of the cationic surfactant 
benzyldimethyltetradecylammonium chloride (Zephiramine) at a concentration of 
0.05 mM, which is below its cmc, showed an increased response, as measured by a 
nominal recovery of 69.1% (compared with 62.1%).  However although this appeared on 
viewing to be a significant increase it was not considered to be significantly different 
when accepted statistical treatment (Section 5.3.2) was  applied  (Table 5.5).  At a 
concentration of 2.5 mM, which is above its cmc, the mean nominal recovery was 
significantly reduced to only 22.6%.  This large reduction in response suggests that there 
has been suppression of ionisation, either as a result of the containment of deltamethrin 
within the micelles formed, or as a result of competition at the surface of the droplets 
being ionised. 
 
The observed recovery in samples following the addition of the zwitterionic surfactant 
N-decyl-N, N-dimethyl-3-ammonio-1-propane (Zwittergent 3-10) at a concentration of 152 
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0.5 mM, which is below its cmc, showed a small, but statistically insignificant increase in 
response, as measured by a nominal recovery of 65.2% (compared with 62.1%).  At a 
concentration of 50 mM, which is above its cmc, there was a significant reduction in 
mean nominal recovery to 55.8%. 
 
The observed recovery in samples following the addition of the non-ionic surfactant 
polyoxyethylene 6 lauryl ether (C12E6) at a concentration of 0.001 mM, which is below 
its cmc, showed a statistically significant increase in response, as measured by a nominal 
recovery of 71.5% (compared with 62.1%).  At a concentration of 0.01 mM, which is 
above its cmc, there was a small, but statistically insignificant, reduction in mean nominal 
recovery to 58.3%. 
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Table 5.4  Recovery of deltamethrin from muscle following the addition of 
surfactant at concentrations above and below the critical micelle concentration. 
Sample Treatment Nominal 
Recovery 
(%)
Mean Nominal 
Recovery (%)             
(SD)
Sample Treatment Nominal 
Recovery 
(%)
Mean Nominal 
Recovery (%)             
(SD)
65.8 65.8
60.2 60.2
54.6 62.1 54.6 62.1
64.2 (4.15) 64.2 (4.15)
63.2 63.2
64.7 64.7
70.2 61.9
74.4 71.6
75.3 70.3 61.7 72.6
65.8 (3.94) 82.9 (9.80)
69.8 73.0
66.4 84.4
58.9 22.8
69.0 23.6
59.1 69.1 21.1 22.6
78.9 (8.99) 23.9 (1.13)
69.4 22.6
79.3 21.4
65.2 58.8
67.6 53.7
66.7 65.2 51.9 55.8
61.4 (2.55) 56.7 (2.80)
67.3 58.8
62.8 54.9
63.5 53.5
78.8 62.1
63.2 71.5 53.5 58.3
79.3 (7.04) 63.9 (4.33)
72.0 57.6
72.1 59.4
QC 100 ng/mL QC 100 ng/mL
1 mM SDS 20 mM SDS
0.001 mM C12E6 0.01 mM C12E6
0.1 mM Zephiramine 5 mM Zephiramine
0.5 mM Zwittergent 3-10 5 mM Zwittergent 3-10
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Table 5.5  Statistical Treatment of Deltamethrin Extracted from Muscle Data.  Where calculated t value exceeds the critical value 
(i.e. shows a statistically significant difference) the t values are in bold. 
Sample Sets for Comparison Mean SD F-Test Critical Value for a 
one-tailed test 
(P=0.05)
Are 
SDs 
Equal?
Calculated 
t
Degrees 
of 
Freedom
Critical 
Value, 
P=0.05
Critical 
Value, 
P=0.025
Critical 
Value, 
P=0.01
62.1 4.15
77.6 13.0
62.1 4.15
70.3 3.94
62.1 4.15
72.6 9.80
62.1 4.15
69.1 8.99
62.1 4.15
22.6 1.13
62.1 4.15
65.2 2.55
62.1 4.15
55.8 2.80
62.1 4.15
71.5 7.04
62.1 4.15
58.3 4.33
3.14
2.76
Muscle vs Liver
9.85 5.05 No 2.78 6 1.94 2.45
1.58 10 1.81 2.23
Muscle with Zwittergent 3-10 
added below CMC
2.65 5.05 Yes
Muscle with Zwittergent 3-10 
added above CMC
2.21 5.05 Yes 3.12 10 1.81 2.23 2.76
Muscle with C12E6 added below 
CMC
2.88 5.05 Yes 2.81 10 1.81 2.23 2.76
Muscle with C12E6 added above 
CMC
1.09 5.05 Yes 1.57 10 1.81 2.23 2.76
Muscle with SDS added below 
CMC
0.90 5.05 Yes 3.55 10 1.81 2.23 2.76
Muscle with SDS added above 
CMC
5.58 5.05 No 2.41 7 1.89 2.36 3.00
Muscle with Zephiramine added 
below CMC
4.70 5.05 Yes 1.73 10 1.81 2.23 2.76
Muscle with Zephiramine added 
above CMC
13.2 5.05 No 2.90 22.4 8 1.86 2.31
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5.3.4.2 Liver 
The observed recovery in samples following the addition of the anionic surfactant SDS at 
a concentration of 0.5 mM, which is below its cmc of 7.2 mM, resulted in no significant 
change in mean response, as measured by a nominal recovery of 76.0%, compared with 
77.6% for an untreated quality control sample (Table 5.6).  At a concentration of 10 mM, 
which is above its cmc, there was a significant reduction in mean nominal recovery to 
61.7% (Table 5.7). 
 
The observed recovery in samples following the addition of the cationic surfactant 
Zephiramine at a concentration of 0.05 mM, which is below its cmc, showed a small, but 
statistically insignificant, reduction in mean response, as measured by a nominal recovery 
of 69.7% (compared with 77.6%).  At a concentration of 2.5 mM, which is above its cmc, 
the mean nominal recovery was significantly reduced to only 43.9%. 
 
The observed recovery in samples following the addition of the zwitterionic surfactant 
Zwittergent 3-10 at a concentration of 0.5 mM, which is below its cmc, showed a small, 
but statistically insignificant, increase in mean response, as measured by a nominal 
recovery of 82.7% (compared with 77.6%).  At a concentration of 50 mM, which is above 
its cmc, the mean nominal recovery was significantly reduced to only 48.7%. 
 
The observed recovery in samples following the addition of the non-ionic surfactant 
polyoxyethylene 6 lauryl ether (C12E6) at a concentration of 0.001 mM, which is below 
its cmc, showed a small, but statistically insignificant, increase in mean response, as 156 
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measured by a nominal recovery of 81.4% (compared with 77.6%).  At a concentration of 
0.01 mM, which is above its cmc, the mean nominal recovery was significantly reduced 
to 58.6%. 
 
The significant increases in mean nominal recovery in muscle following addition of SDS, 
either above or below the cmc, supported the premise that the higher nominal recoveries 
obtained for liver tissue was as a result of the endogenous surfactants.  There were no 
significant differences in mean nominal recovery when any of the surfactant types were 
added below their cmc.  This, combined with the fact that there were significant 
reductions in mean nominal recovery in liver for all surfactants added above their cmc, 
suggested  that the concentration of surfactant required to create the promotion of 
ionisation effect was near the optimum in the liver tissues following the stated extraction.  
The reason for the significant increase in response when a non-ionic surfactant was added 
at a concentration below its cmc to muscle was likely to be that the non-ionic surfactant 
was also reducing the droplet size of the mobile phase reaching the mass spectrometer 
and was thereby improving response. 
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Table 5.6  Recovery of deltamethrin from liver following the addition of surfactant 
at concentrations above and below the critical micelle concentration. 
Sample Treatment Nominal 
Recovery 
(%)
Mean Nominal 
Recovery (%)             
(SD)
Sample Treatment Nominal 
Recovery 
(%)
Mean Nominal 
Recovery (%)
94.7 94.7
91.6 91.6
71.9 77.6 71.9 77.6
72.0 (13.0) 72.0 (13.0)
74.5 74.5
60.7 60.7
81.7 62.4
77.6 61.9
69.8 76.0 60.0 61.7
75.7 (6.33) 61.9 (1.03)
83.4 62.8
67.5 60.9
69.2 44.5
69.1 41.8
68.7 69.7 43.7 43.9
70.6 (0.855) 42.0 (1.80)
69.5 46.3
70.8 45.3
85.0 46.8
73.1 50.6
72.4 82.7 43.1 37.0
89.5 (7.92) 50.7 (17.1)
86.2 16.8
89.9 13.7
67.9 62.3
90.4 57.6
87.5 81.4 62.9 58.6
68.9 (10.3) 58.1 (3.28)
84.0 55.0
89.8 55.9
QC 100 ng/mL
1 mM SDS
0.1 mM Zephiramine
20 mM SDS
5 mM Zephiramine
QC 100 ng/mL
0.5 mM Zwittergent 3-10 5 mM Zwittergent 3-10
0.001 mM C12E6 0.01 mM C12E6
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Table 5.7  Statistical Treatment of Deltamethrin Extracted from Liver Data.  Where calculated t value exceeds the critical value 
(i.e. shows a statistically significant difference) the t values are in bold. 
Sample Sets for Comparison Mean SD F-Test Critical Value 
for a one-tailed 
test (P=0.05)
Are 
SDs 
Equal?
Calculated 
t
Degrees 
of 
Freedom
Critical 
Value, 
P=0.05
Critical 
Value, 
P=0.025
Critical 
Value, 
P=0.01
77.6 13.0
76.0 6.33
77.6 13.0
61.7 1.03
77.6 13.0
69.7 0.855
77.6 13.0
43.9 1.80
77.6 13.0
82.7 7.92
77.6 13.0
37.0 17.1
77.6 13.0
81.4 10.3
77.6 13.0
58.6 3.28
Liver with                                                              
SDS added below CMC
4.23 5.05 Yes 0.27 10 1.81 2.23 2.76
Liver with SDS added above 
CMC
154 5.05 No 2.98 5 2.02 2.57 3.36
Liver with Zephiramine added 
below CMC
242 5.05 No 1.49 5 2.02 2.57 3.36
Liver with Zephiramine added 
above CMC
53.0 5.05 No 6.28 5 2.02 2.57 3.36
Liver with Zwittergent 3-10 
added below CMC
2.70 5.05 Yes 0.82 10 1.81 2.23 2.76
Liver with Zwittergent 3-10 
added above CMC
1.73 5.05 Yes 4.63 10 1.81 2.23 2.76
Liver with C12E6 added below 
CMC
1.59 5.05 Yes 0.56 10 1.81 2.23 2.76
Liver with C12E6 added above 
CMC
15.7 5.05 No 3.47 6 1.94 2.45 3.14
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5.3.5  Addition of surfactant to pure standards 
 
Solutions containing deltamethrin at a concentration equivalent to that found in sample 
extracts, dissolved in the same solvent mixture as those extracts, were prepared.  Sub-sets 
of samples had each of the surfactants previously investigated added at concentrations 
both above and below the relevant cmc.  These were injected on the same 
chromatographic system as the sample extracts. The aim of this experiment was to see if 
the addition of surfactant could be considered as a method of increasing sensitivity in 
samples of any nature, i.e. as a generic means of increasing sensitivity. 
 
Samples containing both anionic and cationic surfactants below their cmc (Table 5.8) 
showed statistically significant increases in response of 16% and 15% respectively.  
Samples containing zwitterionic and non-ionic surfactants below their cmc showed small, 
but statistically insignificant increases in response of 2% and 5% respectively.  Samples 
containing SDS (anionic surfactant) above its cmc showed a significant increase in 
response of 20% (Table 5.9); whereas samples containing all other types of surfactant, 
above their cmc, showed no significant change in response to untreated samples 
(Table 5.10). 160 
 
 
Table 5.8  Addition of surfactants at concentrations below their CMC to pure standards. 
Surfactant Final Surfactant Concentration 
in Sample (mM)
Nominal 
Recovery (%)
Mean Nominal 
Recovery (%)
Absolute 
Recovery (%)
100.7
102.2
105.7
88.4
92.1
92.8
110.0
114.4
115.7
110.1
109.6
110.6
110.5
117.5
111.6
111.2
114.4
109.9
103.6
102.9
102.6
94.6
95.0
98.1
103.9
107.7
102.3
101.0
98.4
98.4
No surfactant present
Sodium 1-dodecanesulphonate                     
(SDS)
Benzyldimethyltetradecylammonium 
chloride (Zephiramine)
100.0
115.2
116.0
N-decyl-N, N-dimethyl-3-ammonio-1-
propane (Zwittergent 3-10)
Polyoxyethylene 6 lauryl ether                               
(C12E6)
n/a 97.0
10 mM 111.7
2.5 mM 112.5
50 mM 99.5 102.6
0.1 mM 102.0 105.1
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Table 5.9 Addition of surfactants at concentrations above their CMC to pure standards. 
Surfactant Final Surfactant Concentration 
in Sample (mM)
Nominal 
Recovery (%)
Mean Nominal 
Recovery (%)
Absolute 
Recovery (%)
100.7
102.2
105.7
88.4
92.1
92.8
109.7
119.2
115.8
116.0
118.6
120.0
109.2
89.2
85.5
109.6
92.7
85.2
99.3
95.8
94.7
98.8
94.4
97.7
94.1
98.2
100.6
95.4
99.6
103.4
No surfactant present n/a 97.0 100.0
Sodium 1-dodecanesulphonate                     
(SDS)
10 mM 116.6 120.2
Benzyldimethyltetradecylammonium 
chloride (Zephiramine)
2.5 mM 95.2 98.2
N-decyl-N, N-dimethyl-3-ammonio-1-
propane (Zwittergent 3-10)
50 mM 96.8 99.8
Polyoxyethylene 6 lauryl ether                               
(C12E6) 0.1 mM 98.6 101.6
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Table 5.10  Statistical treatment of pure standard data. 
Sample Sets for Comparison Mean SD F-Test Critical Value 
for a one-tailed 
test (P=0.05)
Are 
SDs 
Equal?
Calculated 
t
Degrees 
of 
Freedom
Critical 
Value, 
P=0.05
Critical 
Value, 
P=0.025
Critical 
Value, 
P=0.01
97.0 6.81
111.7 2.62
97.0 6.81
116.6 3.77
97.0 6.81
112.5 2.89
97.0 6.81
95.2 11.3
97.0 6.81
99.5 4.10
97.0 6.81
96.8 2.11
97.0 6.81
102.0 3.55
97.0 6.81
98.6 3.43
N.B.   Where the calculated t value exceeds the critical value (showing statistically significant differences) the t values are in bold
2.76 0.51 10 1.81 2.23
Pure standard with C12E6 added 
above CMC
3.93 5.05 No
3.14
Pure standard with C12E6 added 
below CMC
3.68 5.05 Yes 1.60 10 1.81 2.23 2.76
0.07 6 1.94 2.45
Pure standard with Zwittergent       
3-10 added above CMC
10.3 5.05 No
2.76
Pure standard with Zwittergent       
3-10 added below CMC
2.76 5.05 Yes 0.77 10 1.81 2.23 2.76
0.34 10 1.81 2.23
Pure standard with Zephiramine 
added above CMC
2.75 5.05 Yes
2.76
Pure standard with Zephiramine 
added below CMC
5.52 5.05 No 5.13 7 1.89 2.36 3.00
6.18 10 1.81 2.23
Pure standard with SDS added 
above CMC
3.27 5.05 Yes
Pure standard with SDS added 
below CMC
6.72 5.05 No 4.93 7 1.89 2.36 3.00
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5.4  Conclusions 
 
The addition of both anionic and cationic surfactants to samples containing deltamethrin 
causes an increased response that may be considered to be promotion of ionisation, in a 
reproducible and robust manner.  This increase in response was seen both in samples of 
extracted tissue and in pure standard solutions; therefore the emulsification of fats and 
oils by the surfactants was not the only mechanism by which the enhancement was 
achieved.  The presence of surfactants in the samples investigated appears to have 
affected the formation of droplets by the mobile phase, thereby ultimately enhancing the 
detected signal.  
 
Although the increased response may not appear great, i.e. was less than an order of 
magnitude, it was nevertheless of suitable significance that it may be considered as a way 
of improving sensitivity when problems achieving a required limit of detection occur.  
With similar methods to this, where the purpose is to determine that the analyte residue 
level in tissues is below a certain concentration, the typical dynamic range of an assay is 
4-fold, (e.g. 1-4 ng.mL
-1); therefore increases in sensitivity of 20% or more may be 
extremely significant in achieving the required lower limit of quantification.  The data 
reported refers to deltamethrin only; however the data represents an important 
contribution with respect to the overall need of greater understanding of factors affecting 
ionisation.  Such small increases in the linear dynamic range would be less significant in 
a typical method for the analysis of drugs in biological fluids (or tissues) where 
concentration profiles are required.  However, with optimisation, perhaps there is scope 164 
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for producing greater enhancement in a controlled fashion.  Further it might be 
considered that the addition of surfactant might result in greater robustness of the method, 
by reducing the dependency on the variable amount of natural surfactant that survives the 
sample preparation (solid phase extraction) process. 
 
Following  this  investigation, there are  a number of further investigations of this 
phenomenon that suggest themselves.  Initially the same technique could be adopted to 
determine the impact on a wider range of analytes, in order to determine whether this has 
the potential to be available as a generic technique for the promotion of ionisation.  This 
is likely to be the case with tissue samples as used in the initial investigation, but may not 
be so applicable for all samples.  The medium and longer term effects of the use of the 
surfactants on the mass spectrometer performance should also be considered. 
 
Further investigations to determine the optimum surfactant concentration or  range of 
surfactant concentrations using several different analytes could enable a standard 
methodology to be prepared, either for all analytes, or for various types of analyte.  
Alternatively if greater enhancement was to be found with certain classes of analyte, this 
might shed further light on the nature of the phenomenon. 
 
Interestingly, it is accepted wisdom that MEKC-MS (micellar electrokinetic 
chromatography, where separation is based on differential partitioning between a pseudo-
stationary micellar phase and an aqueous mobile phase) can’t be done because of the 
presence of micelles.  Further investigations are required in order to resolve the apparent 165 
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contradiction in this investigation to accepted thinking on the effect of micelles on MS 
analysis. 
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Chapter 6 
 
 
Conclusions and Further Work 
 
 
 
Principally, even before the outset of this research programme, as  a result of the 
introduction of the current generation of atmospheric pressure ionisation interfaces, liquid 
chromatography coupled with tandem mass spectrometric detection had  become the 
analytical method of choice for the determination of pharmaceutical compounds and their 
metabolites.  Despite this there  had  remained  a number of problems associated with 
developing reliable and robust assays for a number of combinations of pharmaceutical 
compound and sample matrix.  However, during the course of the research programme 
some light was shed on some of the problems and some useful solutions emerged. 
 
Failure to remove large numbers of potentially interfering species  during the sample 
preparation process can lead to competition in the ionisation process, thereby leading to 
reduced signal for the analytes of interest, or to a reduction of robustness of the analytical 
method. 
 
The specificity of multiple reaction monitoring in tandem mass spectrometers may mask 
the coelution of species present in biological samples, which can cause matrix effects.  167 
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Good chromatographic separation from potentially interfering species is essential in order 
to avoid matrix-related suppression (or less commonly promotion) of ionisation.   
 
In order to provide an optimum chromatographic separation, it may be necessary to 
utilise mobile phases that are not ideally compatible with current LC-MS/MS instruments 
and that therefore provide inadequate sensitivity for the compound under investigation.  
In this case it may be possible to reduce or eliminate problems associated with the choice 
of mobile phase by the use of some artefact, such as post-column modification of mobile 
phase, in order to enhance the ionisation to allow the required limits of detection to be 
achieved.  This can be effective to varying degrees depending on the chemical nature of 
the compound being analysed, but as illustrated in the work discussed in Chapter 3 it can 
be relatively easy to increase sensitivity by up to an order of magnitude for many classes 
of compound.  Optimisation of this technique was successfully used to reach the required 
lower limit of quantification which would otherwise not have been possible, without a 
complete overhaul of the methodology available, with the prohibitively problematic 
accompanying issues of time and materials that this might have resulted in. 
 
If an ideal chromatographic separation from matrix components is not possible, due to the 
similarity of the interfering species with the target analytes, then alternative strategies 
need to be employed, such as changing the mode of ionisation [141].  The mode of 
ionisation, i.e. the choice of IonSpray or APCI, may not be significant for some analytes 
that have sufficient sensitivity for both modes of ionisation.  However, as illustrated in 168 
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Chapter 2, it can be critical to the development of methods for some analytes, even when 
sensitivity in both modes seems acceptable. 
 
With regards to the sample preparation stage, the chromatographic separation and the 
mobile phase selected, there are also practical considerations to take into account, where 
“dirty” samples cause blockages within the extremely small orifice, thereby causing a 
gradual loss in sensitivity in the mass spectrometer.  As well as changing sensitivity a 
build up of sample residue can cause a complete blockage of the interface tubing, thereby 
stopping all analyte ions from entering the mass spectrometer.  This therefore becomes a 
particular consideration when dealing with small sample volumes, which make repeat 
injection difficult, or even impossible. 
 
Ultimately all of the above problems are associated with the desire to provide optimum 
conditions for the analytes of interest, to the exclusion of any potential interfering 
species.  A combination of the sample preparation methodology, the mode of ionisation 
and artefacts such as post-column modification of mobile phase can be used to enhance 
the signal for the analyte under investigation. 
 
The examples described in this thesis illustrate that even with a well-defined technique 
there are a number of approaches to improving sensitivity and robustness of methods. 
 
In summary, as evidenced by the studies in this research programme, there are no 
absolute rules  to dealing with analytical problems with API-MS.  However, an 169 
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understanding of the causes of most of the problems, and a choice of strategy to deal with 
problems when they arise,  is required to enable an analyst to develop suitable 
methodologies for the determination of pharmaceuticals and biologicals in bioanalytical 
samples. 
 
There are several main areas of work for further investigation resulting from the data 
discussed in this thesis.  For example, post-column modification of mobile phases in 
order to enhance signals should be optimised for a range of analytes.  This should provide 
information to confirm which types of compound are most readily susceptible to this kind 
of sensitivity enhancement as well as providing an indication of the potential sensitivity 
benefits that can arise as a result of modifying the mobile phase before the injected 
sample enters the mass spectrometer source region.  There are two main ways to perform 
this – either to use the methodology discussed in Chapter 4, or to involve the use of 
column switching, where the analytes are loaded onto a fully retaining column, and are 
then eluted using a mobile phase more suited to API-MS interfaces. 
 
At present the methodology described in Chapter 4 has not yet been commonly reported 
[142]  although modification of mobile phase for example changing from principally 
acetonitrile to methanol has been shown to provide potentially large increases in 
sensitivity (depending on the analyte) [143].  The only “commonly” used post-column 
modification of mobile phase is the so-called “TFA fix” [144].  In this, mobile phases 
containing trifluoroacetic acid (which is known to suppress the signal of polar 
compounds by forming ion pairs with them) are modified post-column with a weaker 170 
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acid.  A modification of this has been used by addition of the modifying agent 
pre-column with some success [145].  Other examples include addition of a basic solution 
to alter the mobile phase pH [146] which has been shown to improve sensitivity by over 
an order of magnitude for some analytes.  However, despite the limited modifications 
reported above, the use of post-column modification of highly aqueous mobile phases to 
enhance sensitivity has not yet been reported.  (Generally it seems preferable to 
completely change the chromatography, etc. in order to improve sensitivity, though as 
discussed it is not always possible, particularly for some chiral separations). 
 
The phenomenon of promotion of ionisation using surfactants provides a huge amount of 
potential for further investigation.  This could consist of a number of separate 
investigations.  The first is to utilise a far wider range of surfactant types and 
concentrations to determine additional information about the ability to enhance analyte 
response as a result of the addition of surfactants.  The surfactant type, even within a 
major surfactant class, could be critical to the effect that has been observed and 
discussed.  A possibly more significant investigation would be to perform similar 
experiments to those discussed in this thesis on a range of compound types.  This could 
initially take the form of investigations into the effect of surfactant on the response of 
pure standards of the appropriate compounds.  This would provide an indication of 
whether the compound itself had enhancement/suppression as a result of the presence of 
surfactants.  Once this was established further investigations into different sample 
matrices would be required (to determine the effect of the surfactant on other potentially 
interfering species within a complex sample matrix).  Finally the impact of different 171 
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sample preparation techniques with the presence of added surfactant could also be 
investigated. 
 
At present there has been no reported work on this phenomenon.  Most work 
investigating surfactants is in the environmental analysis sector where the surfactant is 
the target analyte or group of analytes [147], although investigation of surfactant levels in 
liver tissues has been reported [148].  In no case has the suggestion been made that the 
presence of surfactants can be used to enhance sensitivity. 
 
There will always be scope for improvement in any technology.  However, with the 
benefit of some of the techniques available for improvement in sensitivity and specificity 
discussed in this programme, together with other developments such as a number of new 
interfaces such as those that combine APCI with electrospray [62] the practice of LC-MS 
for drug bioanalysis and other applications is becoming much more reliable and well 
understood. 
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